Singapore-based TransferTo has partnered with the Pan-African Ecobank Group in order to expand financial access and cross-border payments across the region of Africa.

Mbank has partnered with Al Etihad Payments Company (AEP), a Central Bank of the UAE (CBUAE) subsidiary, to introduce the Aani Instant Payment Platform on its mobile application.

Source: Peter Bell 11/04/2024

Liberty Gold Corp. (LGD:TSX; LGDTF:OTCQX) released the results of the first study, a prefeasibility study (PFS), of its flagship Black Pine project in Idaho, reported Canaccord Genuity analyst Peter Bell in an Oct. 10 research note.

"The completion of the prefeasibility study is a key step in advancing the project through permitting, bringing a Black Pine mine much closer to reality," Bell wrote. "This is positive."

885% Gain Possible

Canaccord Genuity has a CA$3.25 per share price target on the Canadian Idaho-based exploration and development company, trading at the time of the report at about CA$0.33 per share, noted Bell. These figures imply a potential return on investment of 885%.

Liberty is rated Speculative Buy.

Specifics of the PFS

Bell presented the details of the Black Pine operation as outlined in the PFS, based on reserves of 3,110,000 ounces (3.11 Moz) of 0.32 grams per ton (0.32 g/t) gold.

Average production is 183,000 ounces per year (183 Koz/year) gold for the first five years, peaking at about 231 Koz. The average annual production, based on a 50,000 ton per day throughput, over a 17-year life of mine (LOM) is 135 Koz.

The PFS has the head grade during years one through five at 0.45 g/t gold. Over the LOM, the head grade is 0.32 g/t gold and gold recoveries, 70.4%.

As for costs, operating costs are low at US$9.10 per ton processed. The all-in-sustaining cost (AISC) is US$1,205 per ounce (US$1,205/oz) of gold for years one through five and US$1,380/oz of gold for the LOM.

"We believe the study highlights a simple, lower-risk and long-lived operation with an attractive cost profile," Bell wrote. "We model Liberty achieving initial production at Black Pine in 2029, based on company disclosure around the permitting process."

Attractive Economics

Bell reported the economics outlined in the PFS for the base case using a US$2,000/oz gold price. The after-tax net present value discounted at 5% (NPV5%) is US$552 million, the internal rate of return (IRR) is 32%, and the payback period is 3.3 years. The strip ratio is low at 1.3.

"Of note is the study's leverage to higher gold prices with an NPV5% of US$1,296M (62% IRR at US$2,600/oz)," Bell wrote. At the same gold price, Canaccord Genuity's estimated NPV5% is higher, at US$1,569.

Bell noted that Liberty could enhance the value of Black Pine in any of four ways, by optimizing the resource and mine planning; delineating additional ounces or feed sources; using electric, maybe even autonomous, mining equipment; and defining options for using renewable energy like solar to potentially lower operating costs more.

How Results Stack Up

The analysts pointed out the similarities and differences between Liberty Gold's PFS and Canaccord Genuity's estimates on Black Pine. Between the two, the capex, AISC, mined throughput, and NPV are consistent, "which we view as positive," Bell wrote.

Among the parameters that differ are unit costs per ton processed, strip ratio, head grade, recovery, and total recovered ounces, all lower in the PFS. Mine life, though, is longer.

"The longer mine life and lower total ounce total equate to a lower number of ounces of annual production," Bell explained.

Process and general and administrative costs are lower in the PFS, which decreases the cutoff and the overall grade when compared to Canaccord Genuity's version. Bell indicated that the lower operating cost per ton, however, is positive.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Liberty Gold Corp. is a billboard sponsor of Streetwise Reports.
2. Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
3. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

Disclosures for Canaccord Genuity, Liberty Gold Corp., October 10, 2024

Analyst Certification Each authoring analyst of Canaccord Genuity whose name appears on the front page of this research hereby certifies that (i) the recommendations and opinions expressed in this research accurately reflect the authoring analyst’s personal, independent and objective views about any and all of the designated investments or relevant issuers discussed herein that are within such authoring analyst’s coverage universe and (ii) no part of the authoring analyst’s compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the authoring analyst in the research, and (iii) to the best of the authoring analyst’s knowledge, she/he is not in receipt of material non-public information about the issuer. Analysts employed outside the US are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity LLC and therefore may not be subject to the FINRA Rule 2241 and NYSE Rule 472 restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account.

Sector Coverage Individuals identified as “Sector Coverage” cover a subject company’s industry in the identified jurisdiction, but are not authoring analysts of the report. Investment Recommendation Date and time of first dissemination: October 10, 2024, 09:56 ET Date and time of production: October 10, 2024, 09:56 ET Target Price / Valuation Methodology: Liberty Gold Corp. - LGD Our target price is based on a 0.85x multiple applied to our forward curve derived operating NAV less net debt and other corporate adjustments. Risks to achieving Target Price / Valuation: Liberty Gold Corp. - LGD In addition to the usual risks to target prices associated with commodity pricing, exchange rates, and mineral exploration/ development, we highlight the following: Commodity price risk: As a precious metals development company, LGD’s future revenue is dependent on the price of gold. Water rights: The Goldstrike Project does not currently have sufficient water rights to operate the proposed mine and heap leach. They announced June 1 that they have retained consultants to attempt to obtain water. Geo-political risk: Liberty is currently focussed on the western United States but retains exposure to Turkey through the TV-Tower project. Accordingly, Liberty’s operations could be adversely impacted by political or economic instability or changes in government policy that impact the ownership of assets, mining activities, exchange rates, taxation, or royalties in Turkey. We note that Liberty’s Turkish asset, TV-Tower, accounts for less than 3% of NAV in our valuation. Mining risk: LGD faces the typical risks inherent to mining companies relating to operating and capital costs, availability of capital, permitting requirements and timelines, technical and operating parameters, reserve and resource models, social license and community relations, taxation and royalty regimes, and regulatory and political risks. Black Pine does not currently have a published economic study so the estimates in our model are based on our own interpretation of how the operation may be designed. As such, our valuation of the Black Pine project may be impacted by differences in strip ratio, CapEx, mining throughput, recovery assumptions, and gold grade. Development risk: LGD is planning to develop the Black Pine and Goldstrike projects in Idaho and Utah respectively. The company faces risks associated with developing the project including capital and operating cost risk, financing, project permitting and timelines, and technical risks to achieve the planned operating rates. Permitting risk: Permitting is still underway at the Black Pine project. As such, the company may not be able to proceed with the project as it is currently envisaged if the required permits are not received in a timely manner. Financing risk: As a pre-cash-flow development company, LGD is reliant on the capital markets to remain a going concern. At present, the company has an estimated cash position of ~US$13.1M (Q2/24), which positions the company well in the near term to continue to advance its portfolio of exploration/development projects, in our view. We note that there is no guarantee that LGD will be able to access capital markets in the future as the result of potential changes in market sentiment/pricing and/or concerns involving project feasibility. As such, there is no guarantee that LGD will be able to secure the required funds to advance the Black Pine project, including but not limited to debt/equity financing and/or a strategic investment.

Required Company-Specific Disclosures (as of date of this publication) Canaccord Genuity or one or more of its affiliated companies intend to seek or expect to receive compensation for Investment Banking services from Liberty Gold Corp. in the next three months.

Past performance In line with Article 44(4)(b), MiFID II Delegated Regulation, we disclose price performance for the preceding five years or the whole period for which the financial instrument has been offered or investment service provided where less than five years. Please note price history refers to actual past performance, and that past performance is not a reliable indicator of future price and/or performance. Online Disclosures Up-to-date disclosures may be obtained at the following website (provided as a hyperlink if this report is being read electronically) http://disclosures.canaccordgenuity.com/EN/Pages/default.aspx; or by sending a request to Canaccord Genuity Corp. Research, Attn: Disclosures, P.O. Box 10337 Pacific Centre, 2200-609 Granville Street, Vancouver, BC, Canada V7Y 1H2; or by sending a request by email to disclosures@cgf.com. The reader may also obtain a copy of Canaccord Genuity’s policies and procedures regarding the dissemination of research by following the steps outlined above.

dissemination of research by following the steps outlined above. General Disclaimers See “Required Company-Specific Disclosures” above for any of the following disclosures required as to companies referred to in this report: manager or co-manager roles; 1% or other ownership; compensation for certain services; types of client relationships; research analyst conflicts; managed/co-managed public offerings in prior periods; directorships; market making in equity securities and related derivatives. For reports identified above as compendium reports, the foregoing required company-specific disclosures can be found in a hyperlink located in the section labeled, “Compendium Reports.” “Canaccord Genuity” is the business name used by certain wholly owned subsidiaries of Canaccord Genuity Group Inc., including Canaccord Genuity LLC, Canaccord Genuity Limited, Canaccord Genuity Corp., and Canaccord Genuity (Australia) Limited, an affiliated company that is 80%-owned by Canaccord Genuity Group Inc. The authoring analysts who are responsible for the preparation of this research are employed by Canaccord Genuity Corp. a Canadian broker-dealer with principal offices located in Vancouver, Calgary, Toronto, Montreal, or Canaccord Genuity LLC, a US broker-dealer with principal offices located in New York, Boston, San Francisco and Houston, or Canaccord Genuity Limited., a UK broker-dealer with principal offices located in London (UK) and Dublin (Ireland), or Canaccord Genuity (Australia) Limited, an Australian broker-dealer with principal offices located in Sydney and Melbourne. The authoring analysts who are responsible for the preparation of this research have received (or will receive) compensation based upon (among other factors) the Investment Banking revenues and general profits of Canaccord Genuity. However, such authoring analysts have not received, and will not receive, compensation that is directly based upon or linked to one or more specific Investment Banking activities, or to recommendations contained in the research. Some regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of research. This research has been prepared in accordance with Canaccord Genuity’s policy on managing conflicts of interest, and information barriers or firewalls have been used where appropriate. Canaccord Genuity’s policy is available upon request. The information contained in this research has been compiled by Canaccord Genuity from sources believed to be reliable, but (with the exception of the information about Canaccord Genuity) no representation or warranty, express or implied, is made by Canaccord Genuity, its affiliated companies or any other person as to its fairness, accuracy, completeness or correctness. Canaccord Genuity has not independently verified the facts, assumptions, and estimates contained herein. All estimates, opinions and other information contained in this research constitute Canaccord Genuity’s judgement as of the date of this research, are subject to change without notice and are provided in good faith but without legal responsibility or liability. From time to time, Canaccord Genuity salespeople, traders, and other professionals provide oral or written market commentary or trading strategies to our clients and our principal trading desk that reflect opinions that are contrary to the opinions expressed in this research. Canaccord Genuity’s affiliates, principal trading desk, and investing businesses also from time to time make investment decisions that are inconsistent with the recommendations or views expressed in this research. This research is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any designated investments discussed herein in any jurisdiction where such offer or solicitation would be prohibited. As a result, the designated investments discussed in this research may not be eligible for sale in some jurisdictions. This research is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. This material is prepared for general circulation to clients and does not have regard to the investment objectives, financial situation or particular needs of any particular person. Investors should obtain advice based on their own individual circumstances before making an investment decision. To the fullest extent permitted by law, none of Canaccord Genuity, its affiliated companies or any other person accepts any liability whatsoever for any direct or consequential loss arising from or relating to any use of the information contained in this research.

Research Distribution Policy Canaccord Genuity research is posted on the Canaccord Genuity Research Portal and will be available simultaneously for access by all of Canaccord Genuity’s customers who are entitled to receive the firm's research. In addition research may be distributed by the firm’s sales and trading personnel via email, instant message or other electronic means. Customers entitled to receive research may also receive it via third party vendors. Until such time as research is made available to Canaccord Genuity’s customers as described above, Authoring Analysts will not discuss the contents of their research with Sales and Trading or Investment Banking employees without prior compliance consent. For further information about the proprietary model(s) associated with the covered issuer(s) in this research report, clients should contact their local sales representative.

Short-Term Trade Ideas Research Analysts may, from time to time, discuss “short-term trade ideas” in research reports. A short-term trade idea offers a near-term view on how a security may trade, based on market and trading events or catalysts, and the resulting trading opportunity that may be available. Any such trading strategies are distinct from and do not affect the analysts' fundamental equity rating for such stocks. A short-term trade idea may differ from the price targets and recommendations in our published research reports that reflect the research analyst's views of the longer-term (i.e. one-year or greater) prospects of the subject company, as a result of the differing time horizons, methodologies and/or other factors. It is possible, for example, that a subject company's common equity that is considered a long-term ‘Hold' or 'Sell' might present a short-term buying opportunity as a result of temporary selling pressure in the market or for other reasons described in the research report; conversely, a subject company's stock rated a long-term 'Buy' or “Speculative Buy’ could be considered susceptible to a downward price correction, or other factors may exist that lead the research analyst to suggest a sale over the short-term. Short-term trade ideas are not ratings, nor are they part of any ratings system, and the firm does not intend, and does not undertake any obligation, to maintain or update short-term trade ideas. Short-term trade ideas are not suitable for all investors and are not tailored to individual investor circumstances and objectives, and investors should make their own independent decisions regarding any securities or strategies discussed herein. Please contact your salesperson for more information regarding Canaccord Genuity’s research.

For Canadian Residents: This research has been approved by Canaccord Genuity Corp., which accepts sole responsibility for this research and its dissemination in Canada. Canaccord Genuity Corp. is registered and regulated by the Canadian Investment Regulatory Organization (CIRO) and is a Member of the Canadian Investor Protection Fund. Canadian clients wishing to effect transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity Corp. in their particular province or territory. For United States Persons: Canaccord Genuity LLC, a US registered broker-dealer, accepts responsibility for this research and its dissemination in the United States. This research is intended for distribution in the United States only to certain US institutional investors. US clients wishing to effect transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity LLC. Analysts employed outside the US, as specifically indicated elsewhere in this report, are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity LLC and therefore may not be subject to the FINRA Rule 2241 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. For United Kingdom and European Residents: This research is distributed in the United Kingdom and elsewhere Europe, as third party research by Canaccord Genuity Limited, which is authorized and regulated by the Financial Conduct Authority. This research is for distribution only to persons who are Eligible Counterparties or Professional Clients only and is exempt from the general restrictions in section 21 of the Financial Services and Markets Act 2000 on the communication of invitations or inducements to engage in investment activity on the grounds that it is being distributed in the United Kingdom only to persons of a kind described in Article 19(5) (Investment Professionals) and 49(2) (High Net Worth companies, unincorporated associations etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended). It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. This material is not for distribution in the United Kingdom or elsewhere in Europe to retail clients, as defined under the rules of the Financial Conduct Authority. For Jersey, Guernsey and Isle of Man Residents: This research is sent to you by Canaccord Genuity Wealth (International) Limited (CGWI) for information purposes and is not to be construed as a solicitation or an offer to purchase or sell investments or related financial instruments. This research has been produced by an affiliate of CGWI for circulation to its institutional clients and also CGWI. Its contents have been approved by CGWI and we are providing it to you on the basis that we believe it to be of interest to you. This statement should be read in conjunction with your client agreement, CGWI's current terms of business and the other disclosures and disclaimers contained within this research. If you are in any doubt, you should consult your financial adviser. CGWI is licensed and regulated by the Guernsey Financial Services Commission, the Jersey Financial Services Commission and the Isle of Man Financial Supervision Commission. CGWI is registered in Guernsey and is a wholly owned subsidiary of Canaccord Genuity Group Inc. For Australian Residents: This research is distributed in Australia by Canaccord Genuity (Australia) Limited ABN 19 075 071 466 holder of AFS Licence No 234666. To the extent that this research contains any advice, this is limited to general advice only. Recipients should take into account their own personal circumstances before making an investment decision. Clients wishing to effect any transactions in any financial products discussed in the research should do so through a qualified representative of Canaccord Genuity (Australia) Limited or its Wealth Management affiliated company, Canaccord Genuity Financial Limited ABN 69 008 896 311 holder of AFS Licence No 239052. This report should be read in conjunction with the Financial Services Guide available here - Financial Services Guide. For Hong Kong Residents: This research is distributed in Hong Kong by Canaccord Genuity (Hong Kong) Limited which is licensed by the Securities and Futures Commission. This research is only intended for persons who fall within the definition of professional investor as defined in the Securities and Futures Ordinance. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. Recipients of this report can contact Canaccord Genuity (Hong Kong) Limited. (Contact Tel: +852 3919 2561) in respect of any matters arising from, or in connection with, this research.

Additional information is available on request. Copyright © Canaccord Genuity Corp. 2024 – Member CIRO/Canadian Investor Protection Fund Copyright © Canaccord Genuity Limited. 2024 – Member LSE, authorized and regulated by the Financial Conduct Authority. Copyright © Canaccord Genuity LLC 2024 – Member FINRA/SIPC

Copyright © Canaccord Genuity (Australia) Limited. 2024 – Participant of ASX Group, Cboe Australia and of the NSX. Authorized and regulated by ASIC. All rights reserved. All material presented in this document, unless specifically indicated otherwise, is under copyright to Canaccord Genuity Corp., Canaccord Genuity Limited, Canaccord Genuity LLC or Canaccord Genuity Group Inc. None of the material, nor its content, nor any copy of it, may be altered in any way, or transmitted to or distributed to any other party, without the prior express written permission of the entities listed above. None of the material, nor its content, nor any copy of it, may be altered in any way, reproduced, or distributed to any other party including by way of any form of social media, without the prior express written permission of the entities listed above.

( Companies Mentioned: LGD:TSX; LGDTF:OTCQX, )

Source: Streetwise Reports 11/06/2024

Golden Cariboo Resources Ltd. (GCC:CSE; GCCFF:OTC; A0RLEP:WKN; 3TZ:FSE) has reported encouraging results from its 2024 field campaign. During the exploration, the company collected 16 rock samples from the Halo zone, North Hixon zone, and Pioneer area. These samples revealed promising gold mineralization in the region. Notable highlights from the Halo zone include grab samples from newly exposed outcrops, with assays reaching 8.47 g/t Au (grams per tonne, gold), 6.59 g/t Au, and 2.39 g/t Au. These samples were taken from altered andesite tuff with quartz-carbonate veins located approximately 101 meters northeast of the nearest drill collar.

Sampling near the Pioneer showing, situated one-kilometer north-northwest of the Halo zone, also returned assays of 1.13 g/t Au and 0.40 g/t Au. The fieldwork's findings have significantly extended the strike length of known gold mineralization by one kilometer and expanded the surface footprint of mineralization to the northeast. Despite challenging glacial cover, Golden Cariboo's team continues to uncover significant gold-bearing outcrops.

The report also underscored the strategic advantages of the property's location, infrastructure, and proximity to Highway 97, which reduces exploration and operational costs. Wortel detailed Golden Cariboo's drilling campaign, which includes results such as Hole QGQ24-013, which intersected 136.51 meters at 1.77 g/t gold, including a higher-grade interval of 23.89 meters at 3.32 g/t gold.

Valuation metrics from the report included a projected fair value of CA$0.40 per share, representing a 74% potential upside from the current trading price of CA$0.23, and doesn't include the added value from recent, significant exploration success. Despite acknowledging the high risks associated with early-stage exploration projects, Couloir Capital emphasized the long-term value potential in a Tier 1 mining jurisdiction, reinforced by the company's experienced management team and promising geological trends.

Frank Callaghan, President and CEO of Golden Cariboo, stated in the news release, "Although there is a lot of glacial cover on this project, our geologists still managed to find new gold-bearing outcrops in areas of great significance. We have now expanded the surface footprint of gold mineralization at the Halo zone to the northeast and increased the strike length of our gold trend. We're in a very large gold system that is being demonstrated by multiple, varied work programs."

Mining and Metals Market

On October 29, Kitco reported that gold prices had reached nearly US$2,800. This price represents a 35% increase for the year. The rise was attributed to multiple factors, including "geopolitical conflicts, Federal Reserve interest rate normalization, continued strong demand from global central banks, and uncertainties about the upcoming presidential election and potential fiscal stimulus." Analysts at Kitco described this combination of elements as a "perfect storm." They noted it had driven investor sentiment and reinforced gold's value as a hedge against economic turmoil.

LiveMint, on October 30, highlighted the substantial returns seen in gold over the past year. Despite this impressive performance, some analysts expressed caution regarding gold's future trajectory. Ajay Kedia, Director of Kedia Advisory, suggested that while gold prices may see a short-term rally, "investors may have to remain cautious on the yellow metal in the second half of 2025." Kedia noted that gold prices could experience profit-taking and a slowdown if interest rate cuts by the Federal Reserve do not materialize as quickly as expected. Nonetheless, gold has continued to serve as a preferred asset for those seeking stability, especially in times of economic and political uncertainty.

In a November 4 report, Egon von Greyerz, Founder and Chairman of Matterhorn Asset Management, provided a historical perspective on gold's role in preserving wealth. Von Greyerz discussed how gold had consistently retained value, even as fiat currencies depreciated over time. He emphasized, "Gold held in the investor's name in safe vaults and jurisdictions outside the financial system is the ultimate form of wealth preservation." Von Greyerz also pointed to gold's outperformance since the 1970s, stating that gold had increased 78 times since President Nixon ended the gold standard in 1971. He argued that gold's journey was "only starting now," citing the ongoing destruction of fiat money value through global debt expansion and monetary policies.

Cariboo Catalysts

According to Golden Cariboo Resources' Q1 2024 investor presentation, the company is advancing exploration on its 3,814-hectare Quesnelle Gold Quartz Mine property, located in British Columbia's historic Cariboo Mining District. The asset benefits from 160 years of mining history and is road-accessible, facilitating year-round exploration. The 2024 exploration program, including trenching and a proposed 2,500-5,000m Phase 2 drilling campaign, aims to delineate the gold system further and complete a National Instrument 43-101 compliant resource estimate.

The property, encircled by Osisko Development Corp. on three sides, holds the potential for high-grade, multi-ounce gold targets. Management is focusing on a multi-phase exploration strategy. This includes trenching to assess shallow overburden and mapping and sampling to refine drill targets. The team's experience and the property's historical and geological significance position Golden Cariboo as a promising exploration venture.

The proposed drilling and development efforts reflect a systematic approach to unlocking value in this underexplored yet historically significant gold camp as the company progresses toward realizing a resource estimate.

Expert Analysis

Golden Cariboo Resources Inc. received favorable coverage from Couloir Capital in a report released on September 3, 2024. Senior Mining Analyst Ron Wortel issued a Buy recommendation for the company, noting the significant potential for discovering a large gold resource at the Quesnelle Gold Quartz property. Wortel highlighted that the property, located in British Columbia's historic Cariboo Mining District, lies along the same geological trend as Osisko Development's projects, suggesting the possibility of tapping into similar high-grade mineralization systems.

The report also underscored the strategic advantages of the property's location, infrastructure, and proximity to Highway 97, which reduces exploration and operational costs. Wortel detailed Golden Cariboo's drilling campaign, pointing out positive early results, such as Hole QGQ24-08, which intersected 263 meters at 0.29 g/t gold, including a higher-grade interval of 200 meters at 0.58 g/t gold. The analyst described these findings as indicative of "bulk-tonnage targets," with visible gold observed in several drill cores, bolstering the outlook for continued exploration success. [OWNERSHIP_CHART-11131]

Valuation metrics from the report included a projected fair value of CA$0.40 per share, representing a 286% potential upside from the current trading price of CA$0.14. Despite acknowledging the high risks associated with early-stage exploration projects, Couloir Capital emphasized the long-term value potential in a Tier 1 mining jurisdiction, reinforced by the company's experienced management team and promising geological trends.

Ownership and Share Structure

According to Golden Cariboo, management and insiders own 30% of Golden Cariboo Resources. President and CEO Frank Callaghan owns 16.45% or 6.93 million shares; Elaine Callaghan has 0.97% or 0.41 million shares; Director Andrew Rees has 0.79% or 0.33 million shares; and Director Laurence Smoliak has 0.3% or 0.13 million shares.

Retail investors hold the remaining. There are no institutional investors.

The company said it has 50.3 million shares outstanding, 24.83 million warrants, and 3.8 million options.

Its market cap is CA$9.7 million. Over the past 52 weeks, Golden Cariboo has traded between CA$0.08 and CA$0.36 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Golden Cariboo Resources Ltd. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Golden Cariboo Resources Ltd.
3. James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

( Companies Mentioned: GCC:CSE; GCCFF:OTC; A0RLEP:WKN;3TZ:FSE, )

; Credit: /Joy Ho for NPR

Perhaps the only respite pandemic closures brought to my family — which includes two kids under age 6 — was freedom from the constant misery of dripping noses, sneezes and coughs. And statistics suggest we weren't the only ones who had fewer colds last year: With daycares and in-person schools closed and widespread use of masks and hand sanitizer in most communities, cases of many seasonal respiratory infections went down, and flu cases dropped off a cliff.

That reprieve might be ending. Social mixing has been starting up again in much of the U.S. and so have cases of garden-variety sniffles. The Centers for Disease Control and Prevention just warned physicians that RSV, a unpleasant respiratory virus, is surging right now in southern states. And it's not just happening in the U.S. — researchers in the U.K. and Hong Kong found that rhinovirus outbreaks spiked there, too, when COVID-19 lockdowns ended.

My family is at the vanguard of this trend. Right after Washington D.C. lifted its mask mandate a few weeks ago, both my kids got runny noses and coughs, and as soon as they tested negative for COVID-19, my pandemic fears were replaced by a familiar dread. I had visions of sleepless, cough-filled nights, dirty tissues everywhere, and — in short order — my own miserable cold.

"If someone in your house is sick, you're not only breathing in their sick air, you're touching those contaminated surfaces. You're having closer contact, you're having longer exposures," says Seema Lakdawala, a researcher at the University of Pittsburgh School of Medicine, who studies how influenza viruses transmit between people. It can start to feel inevitable that the whole family will get sick.

Take heart, my fellow parents-of-adorable-little-germ-machines! Lakdawala says many strategies we all picked up to fight COVID-19 can also stop the spread of many routine respiratory viruses. In fact, they may be even more effective against run-of-the-mill germs, since, unlike the viruses behind most colds, SARS-CoV2 was new to the human immune system.

Those strategies start with everyone keeping their children home from school, camp and playdates when they're sick and keeping up with any and all vaccinations against childhood illnesses. Beyond that, specialists in infectious disease transmission I consulted offer five more tips for keeping my family and yours healthier this summer.

Tip #1: Hang on to those masks

In pre-pandemic times, it might have seemed like a weird move to put on a mask during storytime with your drippy-nosed kid, but Dr. Tina Tan says that's her top tip. She's a professor of pediatrics at the Feinberg School of Medicine at Northwestern University and a pediatric infectious disease physician at Lurie Children's Hospital in Chicago.

When it comes to influenza, a rhinovirus, or any of the other respiratory bugs constantly circulating, "once these viruses touch your mucous membranes, whether it's your eyes, your nose or your mouth, you do have a chance of contracting it," says Tan. Masks help stop infectious particles and virus-filled droplets from getting into your body.

"You don't need a N95," Tan says. A light-weight surgical mask or homemade cloth mask can work as long as it has two or more layers. The mask-wearing also doesn't have to be constant. "If you're going to be face to face with them — they're sitting in your lap, you're reading to them, you're feeding them, etc. — then I would say wear a mask," Tan advises.

Even better, if it's not too uncomfortable for your sick child, have them wear a mask, Lakdawala says. "If your kids are old enough to wear a mask, that would probably be the best strategy, because then you're reducing the amount of virus-laden aerosols in the environment."

How long should you stay masked-up?

For most respiratory viruses, "the infectious period is probably similar to that of COVID," says Dr. Jennifer Shu, a pediatrician in Atlanta and medical editor of the American Academy of Pediatrics' site HealthyChildren.org. It might technically start a few days before symptoms begin and last for up to two weeks, but your sniffly kids are likely most contagious during those first runny-nosed days Shu says. "You could have kids over [age] 2 wear a mask for the first three or four days of symptoms," she suggests.

And if you can't bring yourself to wear a mask or put one on your child inside your own home to fight a cold, don't worry. Lakdawala has a few more ideas.

Tip #2: Air it out, space it out

When Lakdawala's 5- and 8-year-old kids get sick, "I open the windows, I turn on the fans, I get a lot more air circulation going on in the house," she says — that is, weather and allergies permitting, of course.

"A lot of these viruses tend to circulate more during the colder weather, so where you live is going to determine how much you can open your windows," Tan points out. But certainly, she says, "the better the ventilation, the less likely the viruses are going to get transmitted from one person to another."

What about buying HEPA filter air purifiers, or changing the filter in your heating and air conditioning system? "I would not suggest going out to purchase extra HEPA filters just for this purpose," says Dr. Ibukun Kalu, a pediatric infectious disease physician at Duke University. For hospitals that are treating very contagious and serious pathogens like tuberculosis or SARS-CoV2, those upgrades may be important, she says. "But for all of the other routine viruses, it's routine ventilation."

Kalu says you might also want to think strategically about creating some social distance — when it's possible — like strategically having the parent who tends not to get as sick provide the one-on-one care for the sick kid.

Obviously, you can't isolate a sick child in a room by themselves until they recover, but Lakdawala says not getting too close or for too long can help. When her kids are sick, "I do try to just not snuggle them — keep them a little bit at a distance."

Tip #3: Don't try to be a HAZMAT team

There's good news on the house-cleaning front. "Most of these viruses don't live on surfaces for very long periods of time," says Tan.

The research on exactly how long cold-causing rhinoviruses can survive on surfaces — and how likely they are to remain infectious — isn't definitive. As Dr. Donald Goldmann of Boston Children's Hospital poetically put it in The Pediatric Infectious Disease Journal a couple decades ago, "Despite many years of study, from the plains of Salisbury, to the hills of Virginia, to the collegiate environment of Madison, WI, the precise routes rhinovirus takes to inflict the misery of the common cold on a susceptible population remain controversial." That's still true today, doctors say.

There's some evidence that contaminated surfaces are not very important in the spread of colds. In one little study from the 1980s, a dozen healthy men played poker with cards and chips that "were literally gummy" from the secretions of eight other men who had been infected with a rhinovirus as part of the study. Even after 12 hours of poker, none of the healthy volunteers caught colds.

Shu's take home advice? Be methodical in your cleaning of often-touched surfaces (kitchen table, countertops and the like) with soap and water when everybody's healthy, and maybe add bleach wipes or other disinfectant when someone in your household has a cold. But don't panic.

Tan agrees. "Wipe down frequently-touched surfaces multiple times a day," she says. "But you don't have to go crazy and, like, scour everything down with bleach."

You also don't need to do a lot of extra laundry in hopes of eliminating germs on clothes, towels, dishtowels and the like — that can be exhausting and futile. Instead, just try to encourage kids who are sick to use their own towel — and do what you can to give towels a chance to dry out between uses. "Having some common sense and doing laundry every few days — washing your towels every few days and washing your sheets every couple of weeks — is probably good enough," Shu says. "You don't need to go overboard for run-of-the-mill viruses."

Don't fret that there are germs everywhere and you can't touch anything, says Lakdawala. "If I touch something, that -- in itself — is not infecting me," she notes. Instead, it's getting a certain amount of virus on our hands and then touching our own nose, eyes or mouth that can infect us. "If I just go wash my hands, that risk is gone," Lakdawala says.

You can also skip wearing gloves around the house. "People think that they are safe when they're wearing the gloves — and then they touch their face with their gloves [on]" and infect themselves, she says.

Instead, just make it a habit to wash your hands frequently.

Tip #4: Seriously, just wash your hands

"The same handwashing guidelines for COVID also apply for common respiratory illnesses," Shu says. That is: regular soap with warm water, lathered for about 20 seconds.

"The reason why 20 seconds is recommended is because some studies show that washing your hands shorter than that doesn't really get rid of germs." She warns that there hasn't been a whole lot of research on this, and 20 seconds is not a magic number. "But it is thought that anywhere from 15 to 30 seconds is probably good enough to get rid of most of the germs," she says. (Note: No need to drive your family crazy singing the birthday song twice — y'all have options.)

"Wash your hands before you eat, after you eat, after you go to the bathroom ... if you're changing your child's diaper, et cetera.," says Tan. "And if you're going to use hand sanitizer, it has to be at least 60% alcohol."

"Your hands are probably the most important source of transmission outside of someone really coughing or sneezing in your face," Kalu adds.

Tip #5: Don't give up, but do keep perspective

So, what if your beloved child does cough or sneeze in your face? Should you then forget all this stuff and just give in to the inevitable?

Don't give up, says Lakdawala. "Just because you got one large exposure in your mouth and in close range, it doesn't mean that that was sufficient to initiate an infection," she says. Whether you get sick from that germy onslaught is going to depend on a lot of things — the particular virus, whether the sneeze landed in your mouth or nose, whether you've been exposed to some version of that virus before and more.

One tiny positive side effect of the coronavirus pandemic for Lakdawala has been a broader public understanding of "dose-response" in viral transmission. "Just because somebody breathed on you once doesn't necessarily mean that that's what's going to get you infected," she says.

Consider practicing the swiss cheese model of transmission control, Shu says. "Every layer of protection helps — if you find that wearing a face shield is too much, but you do everything else, you're still going to limit your exposure," she says. Just do what works for you and your family.

This content is from Southern California Public Radio. View the original story at SCPR.org.

A teen gets a dose of Pfizer's COVID-19 vaccine at Holtz Children's Hospital in Miami on May 18. Nearly 7 million U.S. teens and pre-teens (ages 12 through 17) have received at least one dose of a COVID-19 vaccine, so far, the CDC says.; Credit: Eva Marie Uzcategui/Bloomberg via Getty Images

It's been a little more than a month since adolescents as young as 12 became eligible in the United States to receive the Pfizer vaccine against COVID-19, and nearly all reports have been positive: The vaccine is very effective in this age group, and the vast majority of kids experience mild side effects, if any — the same sore arm or mild flu-like symptoms seen among adults who get the shot.

The Centers for Disease Control and Prevention has recommended that everyone 12-years-old and older get vaccinated against COVID-19, and the rollout is well underway: According to the CDC, nearly 7 million U.S. teens and pre-teens (ages 12 through 17) have received at least one dose of a COVID-19 vaccine, so far.

Still, soon after the FDA authorized the use of Pfizer's vaccine in young people, federal agencies began receiving reports of mild chest pain or other signs of possible heart inflammation (known as myocarditis) in a very small percentage of recently vaccinated teens.

CDC director Rochelle Walensky said at a White House briefing Friday that there have been more than 300 cases of heart inflammation reported among more than 20 million teens and young adults who have received one of the vaccines made by Moderna or Pfizer. She said that in the "vast majority" of cases, the inflammation went away.

An expert advisory committee to the health agency is expected to review the cases in more depth at a meeting Friday.

So, in the meantime, should parents of teens hesitate to have their kids vaccinated against COVID-19? Vaccine experts and the American Academy of Pediatrics say no, don't hesitate. It's good for doctors and patients to be aware that there might be a connection between the mRNA vaccines and heart inflammation, and to report to their pediatrician anything they see in that first week after vaccination. But it is also important, the CDC notes, to recognize that even if this does turn out to be an extremely rare side effect of the vaccine, "most patients who received care responded well to medicine and rest and quickly felt better." And the serious risks of COVID -19 — even for young healthy people — outweigh the risks of any possible side effects from the vaccine. Here are some questions you may have, and what's known:

What exactly is myocarditis?

Myocarditis is an inflammation of the heart muscle, and pericarditis, also being investigated, is an inflammation of the sac around the heart.

Long before the pandemic, thousands of cases of myocarditis were diagnosed in the U.S. and around the world each year, often triggered by the body's immune response to infections. SARS-CoV-2 can trigger it, and so can cold viruses, and staph and strep and HIV. Other causes include toxins and allergies.

Symptoms include chest pain and shortness of breath. It's often mild enough to go unnoticed, but a full-blown case in adults can cause arrhythmias and heart failure that require careful treatment with multiple medications, and several months of strict rest. In a case study of seven teenagers who got myocarditis following vaccination published last week in the journal Pediatrics, all seven got better after routine treatment with anti-inflammatory drugs.

Pediatric cardiologist Dr. Stuart Berger of the Northwestern University Feinberg School of Medicine, a spokesperson for the American Academy of Pediatrics, says vaccine-related myocarditis in teens is not all that worrisome. "Although they appear with some symptoms of chest pain, and maybe some findings on EKGs, all of the cases we've seen have been on the mild end of the spectrum," he says.

So, what's the concern?

Several hundred reports about the inflammation have been filed with the federal government's Vaccine Adverse Event Reporting System (VAERS); that's a repository of reports sent in by health professionals and patients about any health events they spot in the hours or days after vaccinations. Many of the events reported turn out to be coincidental — not caused by a vaccine. The database is just meant as a starting point for further investigation and not proof of cause and effect. But as NPR's Geoff Brumfiel noted this week, "when millions of people are vaccinated within a short period, the total number of these reported events can look big."

That said, anecdotes reported by doctors in medical journals and reports to VAERS suggest that both of the mRNA vaccines authorized for use in the U.S. — the Pfizer and Moderna vaccines — might slightly increase the incidence of myocarditis in young people. In 2003, a report in the New England Journal of Medicine estimated the background incidence of myocarditis to be 1.13 cases in 100,000 children per year.

Paul Offit, professor of pediatrics at the Children's Hospital of Philadelphia and a member of a Food and Drug Administration vaccine advisory committee says there likely is a causal link between the heart inflammation some doctors are seeing in these teens and the second dose of vaccine. "I think it's real," he says, but hastens to add that the effect is exceedingly small – based on the data collected so far, maybe one in 50,000 vaccinees between the ages of 16 and 39. "And the good news is at least so far it looks to be transient and self-resolving."

Still, maybe I should wait to get my teen vaccinated and see how this plays out?

Uhm, no, according to several vaccine experts contacted by NPR. And this is where a little math comes in handy.

"Take a stadium full of 100,000 people between the ages of 16 and 39, which is the subset that appears to be at greater risk," Offit says. "Vaccinate all of them, and two might get myocarditis." But if you don't vaccinate any of the 100,000, he estimates that about 1,300 would eventually get COVID-19. And those numbers are likely to increase this winter.

About one in 1,000 children who get COVID-19 have gone on to develop a condition called MIS-C (multisystem inflammatory syndrome in children), says Offit, and most of those kids have had some level of myocarditis. In addition, the new coronavirus has directly caused myocarditis in some children and adults. Which of the two stadiums in Offit's metaphor would have more cases of myocarditis — the vaccinated children or unvaccinated kids — is not known precisely. But Offit says he suspects it would be the unvaccinated group. And there's no doubt that 1,000 unvaccinated children would suffer more COVID-19-related illnesses. "A choice not to get a vaccine is not a choice to avoid myocarditis," he says. "It's a choice to take a different risk — and I would argue a more serious one" — of developing a bad case of COVID-19 or long-COVID or COVID-caused myocarditis.

Are the experts advising their own kids in this age group to get vaccinated?

Yes. "I understand people having concerns," says Dr. Judith Guzman-Cottrill. She's a parent and professor of pediatric infectious diseases at the Oregon Health and Science University, as well as the senior author on a small study that came out this month in the journal Pediatrics. In the report, Guzman-Cottrill and her colleagues analyzed the cases of seven boys around the country who developed myocarditis within four days of receiving the Pfizer-BioNTech vaccine.

She and her family recently faced the vaccination decision for her own 13-year-old daughter — and said a whole-hearted yes to the shot.

Guzman-Cottrill suspects there may turn out to be a slightly increased risk of heart inflammation from vaccination in young people, but she and her co-authors note in the Pediatrics report that a direct cause-and-effect connection — even in these seven cases — has yet to be established. And she's impressed that despite the millions of doses that have so far been delivered to teens, no clear and serious post-vaccination problems have shown up. "The emergency departments and urgent care clinics are not filled with teenagers complaining of chest pain," she says.

She's treated unvaccinated teens who developed severe myocarditis from an infection with the COVID-19 virus, and others who developed COVID-19 pneumonia and respiratory failure. Seeing those teens struggle — teens who lacked the powerful immune protection the vaccine provides — was enough for her to suggest vaccination to her daughter, who got her second vaccination earlier this week.

"She saw it as a pathway back to a normal post pandemic life," Guzman-Cottrill says.

And that's where public health comes in. "We really need a highly vaccinated student body when kids return to the classroom this fall," says Guzman-Cottrill, "so we don't see surges in COVID-19 cases."

Joanne Silberner, a former health policy correspondent for NPR, is a freelance journalist living in Seattle.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Reconstructions from the Daynès Studio in Paris depict a male Neanderthal (right) face to face with a human, Homo sapiens.; Credit: /Science Source

It's something that many of us reckon with: the sense that we're not quite as sharp as we once were.

I recently turned 42. Having lost my grandfather to Alzheimer's, and with my mom suffering from a similar neurodegenerative disease, I'm very aware of what pathologies might lurk beneath my cranium.

In the absence of a cure for Alzheimer's and other forms of dementia, the most important interventions for upholding brain function are preventive — those that help maintain our most marvelous, mysterious organ.

Based on the science, I take fish oil and broil salmon. I exercise. I try to challenge my cortex to the unfamiliar.

As I wrote my recent book, A History of the Human Brain, which recounts the evolutionary tale of how our brain got here, I began to realize that so many of the same influences that shaped our brain evolution in the first place reflect the very measures we use to preserve our cognitive function today.

Being social, and highly communicative. Exploring creative pursuits. Eating a varied, omnivorous diet low in processed foods. Being physically active.

These traits and behaviors help retrace our past, and, I believe, were instrumental in why we remain on the planet today.

And they all were, at least in part, enabled by our brain.

Social smart alecks finish first

The human saga is riddled with extinctions.

By "human," I don't just mean Homo sapiens, the species we belong to, but any member of the genus Homo. We've gotten used to being the only human species on Earth, but in our not so distant past — probably a few hundred thousand years ago – there were at least nine of us running around.

There was Homo habilis, or the "handy man." And Homo erectus, the first "pitcher." The Denisovans roamed Asia, while the more well-known Neanderthals spread throughout Europe.

But with the exception of Homo sapiens, they're all gone. And there's a good chance it was our fault.

Humans were never the fastest lot on the African plains, and far from the strongest. Cheetahs, leopards and lions held those distinctions. In our lineage, natural selection instead favored wits and wiliness.

Plenty of us became cat food, but those with a slight cognitive edge — especially Homo sapiens — lived on. In our ilk, smarts overcame strength and speed in enabling survival.

Ecology, climate, location and just sheer luck would've played important roles in who persisted or perished as well, as they do for most living beings. But the evolutionary pressure for more complex mental abilities would lead to a massive expansion in our brain's size and neurocircuitry that is surely the paramount reason we dominate the planet like no other species ever has.

Much of this "success," if you can call it that, was due to our social lives.

Primates are communal creatures. Our close monkey and ape cousins are incredibly interactive, grooming each other for hours a day to maintain bonds and relationships. Throw in a few hoots and hollers and you have a pretty complex community of communicating simians.

An active social life is now a known preserver of brain function.

Research shows that social isolation worsens cognitive decline (not to mention mental health, as many of us experienced this past year). Larger social networks and regular social activities are associated with mental preservation and slowed dementia progression.

Entwined in this new social life was an evolutionary pressure that favored innovation. Our eventual ability to generate completely novel thoughts and ideas, and to share those ideas, came to define our genus.

As we hunted and foraged together, and honed stones into hand axes, there was a collective creativity at work that gave us better weapons and tools that enabled more effective food sourcing, and, later, butchering and fire. Effectively sharing these innovations with our peers allowed information to spread faster than ever before - a seed for the larger communities and civilizations to come.

Challenging ourselves to new pursuits and mastering new skills can not only impress peers and ingratiate us to our group, but literally help preserve our brain. New hobbies. New conversations. Learning the banjo. Even playing certain video games and simply driving a new route home from work each day, as neuroscientist David Eagleman does, can keep our function high.

Whether it's honing ancient stone or taking up Sudoku, any pursuit novel and mentally challenging may help keep the neural circuits firing.

We really are what we eat

All the while, as we hunted and crafted in new and communal ways, we had to eat. And we did so with an uniquely adventurous palette.

Homo sapiens is among the most omnivorous species on the planet. Within reason we eat just about anything. Whether it's leaves, meat, fungus, or fruit, we don't discriminate. At some point, one of us even thought it might be a good idea to try the glistening, grey blobs that are oysters - and shellfish are, it turns out, among the healthiest foods for our brain.

The varied human diet is an integral part of our story. As was the near constant physicality required to source it.

On multiple occasions over the past 1 to 2 million years climate changes dried out the African landscape, forcing our ancestors out of the lush forest onto the dangerous, wide-open grasslands. As evolution pressured us to create and commune to help us survive, a diverse diet also supported our eventual global takeover.

Our arboreal past left us forever craving the dangling fruits of the forest, a supreme source of high-calorie sugars that ensured survival. Back then we didn't live long enough to suffer from Type 2 diabetes: if you encountered sweets, you ate them. And today we're stuck with a taste for cookies and candy that, given our longer lifespans, can take its toll on the body and brain.

But humans were just as amenable to dining on the bulbs, rhizomes and tubers of the savanna, especially once fire came along. We eventually became adept scavengers of meat and marrow, the spoils left behind by the big cats, who preferred more nutritive organ meat.

As our whittling improved we developed spears, and learned to trap and hunt the beasts of the plains ourselves. There is also evidence that we learned to access shellfish beds along the African coast and incorporate brain-healthy seafood into our diet.

Studying the health effects of the modern diet is tricky. Dietary studies are notoriously dubious, and often involve countless lifestyle variables that are hard to untangle.

Take blueberries. Multiple studies have linked their consumption with improved brain health. But, presumably, the berry-prone among us are also more likely to eat healthy all around, exercise, and make it to level 5 on their meditation app.

Which is why so many researchers, nutritionists, and nutritional psychiatrists now focus on dietary patterns, like those akin to Mediterranean culinary customs, rather than specific ingredients. Adhering to a Mediterranean diet is linked with preserved cognition; and multiple randomized-controlled trials suggest doing so can lower depression risk.

A similar diversity in our ancestral diet helped early humans endure an ever-shifting climate and times of scarcity. We evolved to subsist and thrive on a wide range of foods, in part because our clever brains allowed us access to them. In turn, a similarly-varied diet (minus submitting to our innate sugar craving of course) is among the best strategies to maintain brain health.

All of our hunting, and foraging, and running away from predators would have required intense physical exertion. This was certainly not unique to humans, but we can't ignore the fact that regular exercise is another effective means of preserving brain health.

Being active improves performance on mental tasks, and may help us better form memories. Long before the Peletons sold out, our brains relied on both mental and physical activity.

But overwhelmingly the evidence points to embracing a collection of lifestyle factors to keep our brain healthy, none of which existed in a Darwinian vacuum.

Finding food was as social an endeavor as it was mental and physical. Our creative brains harnessed information; gossiping, innovating, and cooking our spoils around the campfire.

Researchers are beginning to piece together the complex pathology behind the inevitable decline of the human brain, and despite a parade of failed clinical trials in dementia, there should be promising treatments ahead.

Until then, in thinking about preserving the conscious experience of our world and relationships — and living our longest, happiest lives — look to our past.

Bret Stetka is a writer based in New York and an editorial director at Medscape. His work has appeared in Wired, Scientific American, and on The Atlantic.com. His new book, A History of the Human Brain, is out from Timber/Workman Press. He's also on Twitter: @BretStetka.

This content is from Southern California Public Radio. View the original story at SCPR.org.

The dangerous Delta variant of the coronavirus is spreading so quickly in the United States that it's likely the mutant strain will become predominant in the U.S. within weeks, according to a new analysis.

The variant, first identified in India, is the most contagious yet and, among those not yet vaccinated, may trigger serious illness in more people than other variants do, say scientists tracking the spread of infection.

The Delta variant apparently already accounts for at least 14% of all new infections, according to the research analysis posted online Monday of more than 242,000 infections nationwide over the last six months.

Another reason to get vaccinated

"It definitely is of concern," says William Lee, the vice president of science at Helix, which is under contract with the Centers for Disease Control and Prevention to help track the variants.

"Just the fact that it's so transmissible means that it's it's dangerous," Lee says, "and so I think you'll see outbreaks of Delta around the country and more people will get sick from it."

Helix launched the study when researchers spotted a drop in the prevalence of the Alpha variant, a contagious strain first spotted in the U.K. that had quickly become the dominant variant in that country and the U.S.

The researchers discovered the drop in relative frequency of the Alpha variant in their spot checks of strains circulating in the U.S. was due to a rapid increase in two other variants: the Gamma variant, first spotted in Brazil, and the Delta variant. The Gamma variant may be slightly better than the original strain at outmaneuvering the vaccines, researchers say.

"It looks like both of them are going to slowly push out Alpha," says Lee, whose study has not yet been peer-reviewed but has been posted on a pre-print server.

How Delta could prompt another U.S. COVID-19 surge

All the vaccines authorized for use in the U.S. appear, in general, to provide powerful protection against all the variants, including Delta. But the rapid spread of the variants is still raising concern because of the large number of people who remain unvaccinated.

"There still are big portions of the country where the rates of vaccination are quite low," notes Dr. Jeremy Luban, a virologist at the University of Massachusetts Medical School. "And, in fact, the Helix paper shows that this Delta variant is increasing in frequency — the speed at which it's increasing in frequency is greatest in those areas where vaccination rates are lowest."

The Delta variant could trigger yet another moderate surge of infections through many parts of the U.S. because of these pockets of unvaccinated people, according to a recent set of projections from the COVID-19 Scenario Modeling Hub, which is helping the CDC plot the future course of the pandemic.

The projections indicate that infections could start to rise again as soon as some time in July, especially if the vaccination campaign continues to stall.

"For the most part, it's a moderate resurgence," says Justin Lessler, an epidemiologist at Johns Hopkins University who is helping coordinate the hub.

"We're not having massive epidemics at a national level, but we have this kind of continuation of the virus just sticking around and keeping us on our toes," Lessler says. "And in specific places there could be substantial epidemics still."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Patrick Doherty volunteered for a new medical intervention of gene-editor infusions for the treatment of genetically-based diseases.; Credit: /Patrick Doherty

Patrick Doherty had always been very active. He trekked the Himalayas and hiked trails in Spain.

But about a year and a half ago, he noticed pins and needles in his fingers and toes. His feet got cold. And then he started getting out of breath any time he walked his dog up the hills of County Donegal in Ireland where he lives.

"I noticed on some of the larger hill climbs I was getting a bit breathless," says Doherty, 65. "So I realized something was wrong."

Doherty found out he had a rare, but devastating inherited disease — known as transthyretin amyloidosis — that had killed his father. A misshapen protein was building up in his body, destroying important tissues, such as nerves in his hands and feet and his heart.

Doherty had watched others get crippled and die difficult deaths from amyloidosis.

"It's terrible prognosis," Doherty says. "This is a condition that deteriorates very rapidly. It's just dreadful."

So Doherty was thrilled when he found out that doctors were testing a new way to try to treat amyloidosis. The approach used a revolutionary gene-editing technique called CRISPR, which allows scientists to make very precise changes in DNA.

"I thought: Fantastic. I jumped at the opportunity," Doherty says.

On Saturday, researchers reported the first data indicating that the experimental treatment worked, causing levels of the destructive protein to plummet in Doherty's body and the bodies of five other patients treated with the approach.

"I feel fantastic," Doherty says. "It's just phenomenal."

The advance is being hailed not just for amyloidosis patients but also as a proof-of-concept that CRISPR could be used to treat many other, much more common diseases. It's a new way of using the innovative technology.

"This is a major milestone for patients," says Jennifer Doudna of the University of California, Berkeley, who shared a Nobel Prize for her work helping develop CRISPR.

"While these are early data, they show us that we can overcome one of the biggest challenges with applying CRISPR clinically so far, which is being able to deliver it systemically and get it to the right place," Doudna says.

CRISPR has already been shown to help patients suffering from the devastating blood disorders sickle cell disease and beta thalassemia. And doctors are trying to use it to treat cancer and to restore vision to people blinded by a rare genetic disorder.

But those experiments involve taking cells out of the body, editing them in the lab, and infusing them back in or injecting CRISPR directly into cells that need fixing.

The study Doherty volunteered for is the first in which doctors are simply infusing the gene-editor directly into patients and letting it find its own way to the right gene in the right cells. In this case, it's cells in the liver making the destructive protein.

"This is the first example in which CRISPR-Cas9 is injected directly into the bloodstream — in other words systemic administration — where we use it as a way to reach a tissue that's far away from the site of injection and very specifically use it to edit disease-causing genes," says John Leonard, the CEO of Intellia Therapeutics, which is sponsoring the study.

Doctors infused billions of microscopic structures known as nanoparticles carrying genetic instructions for the CRISPR gene-editor into four patients in London and two in New Zealand. The nanoparticles were absorbed by their livers, where they unleashed armies of CRISPR gene-editors. The CRISPR editor honed in on the target gene in the liver and sliced it, disabling production of the destructive protein.

Within weeks, the levels of protein causing the disease plummeted. Researchers reported at the Peripheral Nerve Society Annual Meeting and in a paper published in The New England Journal of Medicine.

"It really is exciting," says Dr. Julian Gillmore, who is leading the study at the University College London, Royal Free Hospital.

"This has the potential to completely revolutionize the outcome for these patients who have lived with this disease in their family for many generations. It's decimated some families that I've been looking after. So this is amazing," Gillmore says.

The patients will have to be followed longer, and more patients will have to be treated, to make sure the treatment's safe, and determine how much it's helping, Gillmore stresses. But the approach could help those struck by amyloidosis that isn't inherited, which is a far more common version of the disease, he says.

Moreover, the promising results potentially open the door for using the same approach to treatment of many other, more common diseases for which taking cells out of the body or directly injecting CRISPR isn't realistic, including heart disease, muscular dystrophy and brain diseases such as Alzheimer's.

"This is really opening a new era as we think about gene-editing where we can begin to think about accessing all kinds of different tissue in the body via systemic administration," Leonard says.

Other scientists who are not involved in the research agree.

"This is a wonderful day for the future of gene-editing as a medicine,"
agree Fyodor Urnov, a professor of genetics at the University of California, Berkeley. "We as a species are watching this remarkable new show called: our gene-edited future."

Doherty says he started feeling better within weeks of the treatment and has continued to improve in the weeks since then.

"I definitely feel better," he told NPR. "I'm speaking to you from upstairs in our house. I climbed stairs to get up here. I would have been feeling breathless. I'm thrilled."

This content is from Southern California Public Radio. View the original story at SCPR.org.

California Gov. Gavin Newsom looks on during a news conference after he toured the newly reopened Ruby Bridges Elementary School on March 16, 2021 in Alameda, California. ; Credit: Justin Sullivan/Getty Images

California on Thursday scheduled a Sept. 14 recall election that could drive Democratic Gov. Gavin Newsom from office, the result of a political uprising largely driven by angst over state coronavirus orders that shuttered schools and businesses and upended life for millions of Californians.

The election in the nation’s most populous state will be a marquee contest with national implications, watched closely as a barometer of the public mood heading toward the 2022 elections, when a closely divided Congress again will be in play.

We’ll get the latest. 

With files from the Associated Press 

Guests: 

Katie Orr, government and politics reporter for KQED; she tweets @1KatieOrr

Lara Korte, California politics reporter at the Sacramento Bee; she tweets @lara_korte

This content is from Southern California Public Radio. View the original story at SCPR.org.

Athletes compete during the cycling portion of the IRONMAN 70.3 Steelhead on June 27, 2021 in Benton Harbor, Michigan. ; Credit: Patrick McDermott/Getty Images for IRONMAN

Whether you’re new to running or you’ve finished your tenth triathlon, we want to hear from you about what motivates you and how that translates into pushing yourself physically. 

Guests: 

Mark Remy, longtime runner and writer in Portland, Oregon; creator of humor website dumbrunner.com; he is the author of many books, including The Runner's Rule Book: Everything a Runner Needs to Know--And Then Some (Runner's World) (Rodale Books, 2009)

Sharon McNary, infrastructure correspondent at KPCC; she finished her 11th Ironman Race last week at Coeur d’Alene; she tweets @KPCCsharon

This content is from Southern California Public Radio. View the original story at SCPR.org.

Copy of the book “Beyond Baseball’s Color Barrier: The Story of African Americans in Major League Baseball, Past, Present, and Future” (Rowman & Littlefield, May 2021)

Most of us are familiar with the story of Jackie Robinson, the first Black player to play baseball in the Major Leagues, and while Jackie’s story is arguably the biggest chapter in the story of how baseball was integrated, there’s plenty more to the story that happened both before and after Jackie broke into the Majors. Author, sports historian and Santa Barbara City College Director of Athletics Rocco Constantino dives into this rich history in his new book “Beyond Baseball’s Color Barrier: The Story of African Americans in Major League Baseball, Past, Present, and Future” where he explores the contributions of major figures like Hank Aaron, Willie Mays and Satchel Paige as well as the lesser known ones of players like Vida Blue, Mudcat Grant and Dwight Gooden.

Today on AirTalk, Constantino joins Larry Mantle to explore the history of Black players in baseball, their fight for recognition and integration into the Major Leagues and the issues of race that persisted well beyond Jackie Robinson breaking baseball’s color barrier.

Guest:

Rocco Constantino, author of “Beyond Baseball’s Color Barrier: The Story of African Americans in Major League Baseball, Past, Present, and Future” (Rowman & Littlefield, May 2021); he is a sports historian and the director of athletics at Santa Barbara City College

This content is from Southern California Public Radio. View the original story at SCPR.org.

A fireworks stand, one of about 25 booths that are open for business, advertises on the first day of fireworks sales for Fourth of July celebrations June 28, 2005 in Fillmore, California.; Credit: David McNew/Getty Images

Every year in the days leading up to Independence Day, we’re flooded with public service announcements warning of the dangers and risks associated with fireworks. In LA County, where most fireworks are illegal, it can be even more dangerous as the area’s risk of fire grows. 

Today on AirTalk, we discuss the challenges in enforcing and responding to the use of illegal fireworks and the growing risks. We also want to hear from listeners. What was your Fourth of July experience like this year with fireworks? Do you think more needs to be done to crack down? Join the conversation by calling 866-893-5722.

We reached out to the Los Angeles Police Department, but the department was not able to accommodate our interview request and says updated data is unavailable at this time.

Guest:

Mike Feuer, Los Angeles city attorney; he tweets @Mike_Feuer

This content is from Southern California Public Radio. View the original story at SCPR.org.

The Solar System is full of its own tricks and treats, so discover some of our favorites below.

For two decades now, and counting, the LANDFIRE program continues to assemble the most easy-to-use, intuitive and complete clearinghouse of remote sensing data products for wildland fire managers. 

Chesapeake Bay Program — Press Release — October 31, 2024

Adult Chinook salmon in Alaska and Canada are in trouble, and USGS WFRC scientists are in a race against the clock to find the cause behind their disappearance and a viable solution. A staple in many diets, this salmon species is considered a lifeblood of the region.

At the Cascades Volcano Observatory, staff use technical skills and creativity to solve complex problems and innovate for the future. Erin personifies the cleverness, craftsmanship and creativity that makes volcano science meaningful and FUN! 

NASA released a workshop report on the UNBOUND-FEW workshop series, which was facilitated in part by Tribal Resilience Learning Network staff from the Alaska CASC. The workshop report reveals key recommendations for making data tools more useful for climate adaptation planning.

USGS Western Fisheries Research Center (WFRC) biological science technician, Genevieve Kent, is the winner of this issue’s photo contest. 

This summer, USGS Western Fisheries Research Center and collaborating scientists were delighted to find that the abundance of wild born juvenile fall Chinook salmon migrating out of the Snake River has increased by almost 2 orders of magnitude within the last 30 years. 

Mauna Loa summit webcams have been down for several months due to wind damage at the radio telemetry site. On November 7, 2024, HVO staff visited the site and performed a partial fix that brought the webcams back online.

At the tops of many mountains and along numerous roads across the USA are small brass disks called benchmarks.  These survey points are critical for mapping the landscape, determining boundaries, and documenting changes, and there are hundreds of them in Yellowstone National Park!

At the Cascades Volcano Observatory, staff use technical skills and creativity to solve complex problems and innovate for the future. Maciej’s experiments are too large for the observatory, so he travels 3 hours southeast of CVO to the HJ Andrews Experimental Forest in Blue River, Oregon to study debris flows. 

Lawmakers in Washington, D.C., have reached a preliminary, bipartisan agreement on police reform after months of closely watched debate on the topic.

Sens. Tim Scott, R-S.C., and Cory Booker, D-N.J., and Rep. Karen Bass, D-Calif., announced the agreement on Thursday evening.

"After months of working in good faith, we have reached an agreement on a framework addressing the major issues for bipartisan police reform," the lawmakers said in a joint statement.

"There is still more work to be done on the final bill, and nothing is agreed to until everything is agreed to. Over the next few weeks we look forward to continuing our work toward getting a finalized proposal across the finish line."

The exact details of the plan were not immediately clear.

The issue of reforming qualified immunity, to make it easier to sue police officers over allegations of brutality, had been a sticking point in negotiations. The police use of chokeholds was another debated provision.

The effort to reform U.S. policing comes after several years of increasing pressure to better understand and regulate the way officers interact with the communities they patrol.

The high-profile deaths of several Black people — many unarmed — at the hands of police — who have in some notable instances been white — have been the catalyst for the police reform movement.

The Democratic-led House had approved the George Floyd Justice in Policing Act — named after one of those Black people killed by police — in early March, and President Biden had hoped Congress would pass the reform effort by the first anniversary of Floyd's death in late May.

But Bass had said then that getting "a substantive piece of legislation" is "far more important than a specific date."

Floyd's murderer, former Minneapolis police officer Derek Chauvin, is set to be sentenced to prison on Friday.

White House press secretary Jen Psaki said in a statement Thursday that Biden "is grateful to Rep. Bass, Sen. Booker, and Sen. Scott for all of their hard work on police reform, and he looks forward to collaborating with them on the path ahead."

The topic of police reform has divided the nation across party lines, with progressives accusing the right of seeking to maintain an antiquated and all-too-powerful law enforcement apparatus. Conservatives say the left has blamed the actions of some officers on the institution itself, turning the topic of police support and "blue lives" into more ammunition for the ongoing culture war.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Assistant Attorney General Kristen Clarke for the Justice Department's Civil Rights Division speaks during a news conference Friday announcing a lawsuit against the state of Georgia for its new voting law. Attorney General Merrick Garland is at right.; Credit: Jim Watson/AFP via Getty Images

Attorney General Merrick Garland announced Friday that the U.S. Justice Department is suing the state of Georgia over its new voting law, saying that the controversial measure is intended to restrict ballot access to Black voters.

"Our complaint alleges that recent changes to Georgia's election laws were enacted with the purpose of denying or abridging the right of Black Georgians to vote on account of their race or color, in violation of Section 2 of the Voting Rights Act," Garland said at a news conference.

The lawsuit marks the first major action from the Biden administration to combat a series of new restrictive voting measures passed by Republican-led state legislatures. And it came on the eighth anniversary of the U.S. Supreme Court decision to gut another key provision of the landmark Voting Rights Act, Section 5.

Garland noted that Georgia experienced record voter turnout and participation in the 2020 election cycle.

In March, Georgia Gov. Brian Kemp, a Republican, signed Senate Bill 202, a 98-page omnibus measure that makes sweeping changes to the state's absentee voting rules, adds new voter identification mandates and nearly cuts in half the amount of time for voters to request a mail-in ballot. It also expands early voting access for most counties and formally codifies Sunday voting hours as optional.

The legislation outlaws passing out food or drinks to voters within 150 feet of a polling place or too close to voters waiting in line, a provision that Assistant Attorney General Kristen Clarke, who heads the department's Civil Rights Division, highlighted at the press conference.

"Historically, minority voters in Georgia have been disproportionately more likely to wait in long lines to vote in person on Election Day," she said. "Given those long and protracted wait times, civic groups, including churches, have at times provided food and water to voters in line to make their wait more comfortable. As we allege in our complaint, this needless ban was passed with unlawful discriminatory intent."

Clarke also said the Georgia Legislature passed the bill through "a rushed process that departed from normal practice and procedure."

"The version of the bill that passed the state Senate ... was three pages long. Days later, the bill ballooned into over 90 pages in the House. The House held less than two hours of floor debate on the newly inflated SB 202 before Gov. Kemp signed it into law the same day," she said. "These legislative actions occurred at a time when the Black population in Georgia continues to steadily increase, and after a historic election that saw record voter turnout across the state, particularly for absentee voting, which Black voters are now more likely to use than white voters."

Garland said the lawsuit is the first of "many steps" the department is taking to protect the right to vote for all eligible voters. He said the Civil Rights Division will continue to examine voting laws that other states have passed.

"We will not hesitate to act," Garland said.

The Justice Department announced this month it would vigorously defend voting rights. Garland said that the department will double the number of voter enfranchisement lawyers and focus attention on litigation related to voting rights.

In response to the filing, Kemp said the lawsuit is "born out of the lies and misinformation the Biden administration has pushed against Georgia's Election Integrity Act from the start."

"[Biden and his allies] are weaponizing the U.S. Department of Justice to carry out their far-left agenda that undermines election integrity and empowers federal government overreach in our democracy," he said in a statement.

Georgia Secretary of State Brad Raffensperger, another Republican who notably defended the state's administration of the 2020 election, said in a statement he "looks forward to ... beating [the administration] in court."

Garland's announcement comes just days after Senate Republicans united to block Democrats' attempts to pass sweeping voting rights legislation.

Senate Judiciary Chairman Dick Durbin, D-Ill., tweeted his approval of the lawsuit shortly after the announcement Friday.

"If Republicans think the fight for voting rights ended with their filibuster of the For the People Act, they are sorely mistaken," he wrote. "Glad to see the Biden Administration is joining this effort. We must protect our democracy."

The Republican National Committee also linked the failed Senate vote to the Department of Justice's lawsuit.

"After failing to sell the partisan federal election takeover known as H.R. 1 to the American people, Joe Biden is now weaponizing the Justice Department to attack election integrity," RNC Chair Ronna McDaniel said in a statement.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Former Alaska Sen. Mike Gravel, who read the Pentagon Papers into the Congressional Record and confronted Barack Obama about nuclear weapons during a later presidential run, has died. He was 91.; Credit: Charles Dharapak/AP

SEASIDE, Calif. — Mike Gravel, a former U.S. senator from Alaska who read the Pentagon Papers into the Congressional Record and confronted Barack Obama about nuclear weapons during a later presidential run, has died. He was 91.

Gravel, who represented Alaska as a Democrat in the Senate from 1969 to 1981, died Saturday, according to his daughter, Lynne Mosier. Gravel had been living in Seaside, California, and was in failing health, said Theodore W. Johnson, a former aide.

Gravel's two terms came during tumultuous years for Alaska when construction of the trans-Alaska oil pipeline was authorized and when Congress was deciding how to settle Alaska Native land claims and whether to classify enormous amounts of federal land as parks, preserves and monuments.

He had the unenviable position of being an Alaska Democrat when some residents were burning President Jimmy Carter in effigy for his measures to place large sections of public lands in the state under protection from development.

Gravel feuded with Alaska's other senator, Republican Ted Stevens, on the land matter, preferring to fight Carter's actions and rejecting Stevens' advocacy for a compromise.

In the end, Congress passed the Alaska National Interest Lands Conservation Act of 1980, a compromise that set aside millions of acres for national parks, wildlife refuges and other protected areas. It was one of the last bills Carter signed before leaving office.

Gravel's Senate tenure also was notable for his anti-war activity. In 1971, he led a one-man filibuster to protest the Vietnam-era draft and he read into the Congressional Record 4,100 pages of the 7,000-page leaked document known as the Pentagon Papers, the Defense Department's history of the country's early involvement in Vietnam.

Gravel reentered national politics decades after his time in the Senate to twice run for president. Gravel, then 75, and his wife, Whitney, took public transportation in 2006 to announce he was running for president as a Democrat in the 2008 election ultimately won by Obama.

He launched his quest for the 2008 Democratic presidential nomination as a critic of the Iraq war.

"I believe America is doing harm every day our troops remain in Iraq — harm to ourselves and to the prospects for peace in the world," Gravel said in 2006. He hitched his campaign to an effort that would give all policy decisions to the people through a direct vote, including health care reform and declarations of war.

Gravel garnered attention for his fiery comments at Democratic forums.

In one 2007 debate, the issue of the possibility of using nuclear weapons against Iran came up, and Gravel confronted then-Sen. Obama. "Tell me, Barack, who do you want to nuke?" Gravel said. Obama replied: "I'm not planning to nuke anybody right now, Mike."

Gravel then ran as a Libertarian candidate after he was excluded from later Democratic debates.

In an email to supporters, he said the Democratic Party "no longer represents my vision for our great country." "It is a party that continues to sustain war, the military-industrial complex and imperialism — all of which I find anathema to my views," he said.

He failed to get the Libertarian nomination.

Gravel briefly ran for the Democratic nomination for president in 2020. He again criticized American wars and vowed to slash military spending. His last campaign was notable in that both his campaign manager and chief of staff were just 18 at the time of his short-lived candidacy.

"There was never any ... plan that he would do anything more than participate in the debates. He didn't plan to campaign, but he wanted to get his ideas before a larger audience," Johnson said.

Gravel failed to qualify for the debates. He endorsed Vermont Sen. Bernie Sanders in the contest eventually won by now-President Joe Biden.

Gravel was born Maurice Robert Gravel in Springfield, Massachusetts, on May 13, 1930.

In Alaska, he served as a state representative, including a stint as House speaker, in the mid-1960s.

He won his first Senate term after defeating incumbent Sen. Ernest Gruening, a former territorial governor, in the 1968 Democratic primary.

Gravel served two terms until he was defeated in the 1980 Democratic primary by Gruening's grandson, Clark Gruening, who lost the election to Republican Frank Murkowski.

This content is from Southern California Public Radio. View the original story at SCPR.org.

President Biden plans to visit the Champlain Towers condo collapse later this week.; Credit: Lynne Sladky/AP

The White House says President Biden and first lady Jill Biden will travel to Florida Thursday to view first hand the partial collapse of the Champlain Towers condominium.

Asked by reporters if he planned to visit Surfside, Biden said, "Yes I hope so, as soon as we can. Maybe as early as Thursday." The White House issued a formal announcement of the trip shortly afterward.

The official death toll in the collapse has risen to 11, with some 150 people unaccounted for.

The Biden administration has responded to the disaster, dispatching FEMA administrator Deanne Criswell to the scene earlier this week.

"[The agency] has deployed an Incident Management Assistance Team, as well as building science experts, structural engineers and geotechnical experts to support search-and-rescue operations, and a mobile command center," White House press secretary Jen Psaki said Monday.

Psaki said the U.S. Army Corps of Engineers is also providing technical assistance for debris removal. Two FEMA-supported search-and-rescue teams are also involved in the response to the collapse.

Florida Gov. Ron DeSantis has praised FEMA and the Biden administration for "stepping up to the plate" in providing assistance in the search and recovery effort. Miami-Dade Mayor Daniella Levine Cava said Biden's upcoming trip would be "an important reminder that our county, our state and our nation are giving everything we have to search for the victims of this tragedy and support the families in this incredibly devastating time."

Here's what we know about what led to the collapse. Follow more coverage on the aftermath here.

Florida Division of Emergency Management is urging people with information about loved ones who are either unaccounted for or known to be safe to call 305-614-1819.

This content is from Southern California Public Radio. View the original story at SCPR.org.

According to one new account of the Trump presidency, even telling the story of President Trump's Covid diagnosis was difficult due to the chaos in the white house. Here, Trump removes his protective mask after being discharged from the Walter Reed National Military Medical Center with Covid-19.; Credit: Bloomberg/Bloomberg via Getty Images

When the Wall Street Journal's Michael Bender wrote his book about Donald Trump's 2020 defeat, one section stuck out as particularly difficult: telling the story of what Bender dubbed "Hell Week-And-A-Half."​

"It was the ten days in 2020 that started with the super spreader event in the Rose Garden, included the Trump's disastrous debate with Joe Biden in Cleveland, and then Trump himself obviously testing positive for COVID a few days later," Bender said.

It's not just that it was a lot to fold together; it's that simply figuring out what happened was maddening.​

"How early he tested positive, how sick he was during that time — I mean, these are serious questions with national security implications that very few people knew or had firsthand knowledge of, and I had competing versions from senior officials, serious people who all were telling me different versions of that story," he said.

Bender's Frankly, We Did Win This Election is one of many books trying to pull order from Trump's chaos, and that struggle to discern the truth, he explains, is itself emblematic of the Trump administration.​

"The deception wasn't just with the public. It was literally from person to person inside the West Wing," he said. "And that's the story — not necessarily worrying about exactly what happened, which will have to come out at some later point, if it ever does."

Former officials are judging Trump's election lies and pandemic response poorly

Judging from the excerpts that have been released, this first wave of post-Trump-presidency books is filled with behind-closed-doors details — like, for example, how gravely ill Trump was with COVID-19, or former Attorney General William Barr's blunt assessment about Trump's claims of a rigged election: "​My suspicion all the way along was that there was nothing there. That it was all bulls***," as ABC's Jonathan Karl recounts.

But the challenge of recounting this chapter of American history is not just about recounting news-making moments — the racist statements, the allegations of sexual assault, the impeachments — but making sense of it.​

Yasmeen Abutaleb, who coauthored the forthcoming Nightmare Scenario with her Washington Post colleague Damian Paletta, agreed that it was hard to discern the truth from dozens of conflicting stories from within the White House.

But that made it all the more striking when they did find consensus on the Trump White House's coronavirus response. "Of the more than 180 people we spoke to, there wasn't a single one who defended the collective response," she said.

Writing this book, she added, allowed her and Paletta to come away with a clearer assessment of the Trump White House's pandemic response than they gleaned from their day-to-day coverage last year.

"Coronavirus was going to be a challenge no matter who was in charge," she said. "But when we looked at the number of opportunities there were to turn the response around, many of which we didn't know about at the time or couldn't learn it at the time, I think we were shocked at the number of opportunities there were and how they weren't taken."

In addition to the challenge of telling complete, ordered stories of a chaotic presidency, there is also the challenge of placing that presidency into historical context, says Princeton presidential historian Julian Zelizer. He's working with a team of historians to pull together a history of the Trump administration.

"Why did America's political system have room for so much chaos over a four year period? Which is this big puzzle I don't think everyone's totally grappled with," he said.

It's not just journalists and historians. Trump-administration insiders will try to explain their place in history. That's according to Keith Urbahn, a co-founder of Javelin, a literary agency that represented Bender, former UN ambassador John Bolton, and former FBI director James Comey, with more to come.​

"I think it does require for people who worked in the Trump presidency to wrestle with some of the moral compromises that they had to make by serving in that administration," he said.

Post-Trump chaos is rippling through the publishing world

Writing the history of a leaky, live-tweeted presidency has been unusual for a variety of additional reasons. There's book industry tumult — Simon and Schuster employees protested the publishing giant over printing former Vice President Mike Pence's book.

In addition, Trump could still run for president again, which may be why he has given at least 22 book interviews, Axios recently reported. (He has also said he is writing the "book of all books," though some major publishers are hesitant about publishing it, Politico has reported.)

The Trump era was also unusual for the book industry in another way.

"We can honestly say that the four years of the Trump administration were four of the strongest years cumulatively for political books since we've been tracking books, which started in 2001," said Kristen McLean, executive director and industry analyst at market research firm NPD.

Now, however, those sales moving back towards a pre-Trump normal — political book sales are down 60% from the second half of 2020, McLean said.

But that doesn't mean interest will disappear, according to Javelin co-founder Matt Latimer.​

"For example, next year there are a dozen or more books coming out about President Nixon," he said. "I mean, I think long after we're all gone, people are going to be trying to figure out what the hell this was all about."

It's been 47 years since Nixon resigned. By that same math, we'll be reading new Trump books into the late 2060s — and probably beyond.

This content is from Southern California Public Radio. View the original story at SCPR.org.

The closely-watched New York City mayoral primary election tumbled into chaos this week as the NYC Board of Elections announced it had released incorrect preliminary results on Tuesday.

City officials admitted they failed to remove 135,000 test ballots from the election management system before starting to count the real votes from Election Day and early voting, skewing the results.

"The Board apologizes for the error and has taken immediate measures to ensure the most accurate up to date results are reported," the agency tweeted.

The error is complicated by the fact that New York City is using ranked-choice voting, in which each round of vote counting hinges on the results from the previous round.

Some of the top candidates vying to lead the country's largest city blasted the board's mistake as they — and about 8.5 million other New Yorkers — awaited the results of a revised tally expected to be released on Wednesday.

Ranked-choice voting, explained

Instead of choosing just one candidate to vote for, New York City voters in last week's election were able to rank their top five candidates in order of preference.

It was the first time in decades New York used ranked-choice voting, which city voters overwhelmingly approved in a 2019 ballot measure.

NPR's Domenico Montanaro explained how the process works:

1. "If someone gets 50% plus one after all the first-choice votes are counted, then the election is over and that candidate wins. 
2. "But if no one gets 50% plus one, it's on to Round 2.
3. "The person with the lowest number of first-place votes is eliminated, and that candidate's voters' second choices get redistributed as votes for other candidates.
4. "This reallocation of votes goes on until someone reaches 50% plus one."

If just two candidates remain at the end, the candidate with the most votes wins.

What happened this week

On Tuesday, the city Board of Elections released the first ranked-choice voting reports from the election.

With only first-preference votes counted as of election night, Brooklyn Borough President Eric Adams boasted a nine-point lead over attorney Maya Wiley. Those first reported ranked-choice results shrank Adam's lead to just two points ahead of former Sanitation Commissioner Kathryn Garcia, Gothamist reported.

But just hours later, the board tweeted that it had become aware of a "discrepancy" in the ranked-choice voting results and pulled them from its website.

In a follow-up apology, the board acknowledged that it had erroneously left 135,000 test votes in its election system, producing "additional records" that likely impacted an accurate tally.

"At this point it really seems like an issue of human error," WNYC reporter Brigid Bergin told NPR's Morning Edition.

"The board does conduct a lot of pre-election testing to make sure their systems are working and, obviously, that was even more important this time, because it was the first time they were using this new ranked-choice voting system," she added.

Bergin said the board is expected to release a corrected ranked-choice voting report Wednesday, but it will still be preliminary and it won't include 124,000 absentee ballots.

How the candidates are reacting

All of the mayoral contenders expressed frustration with the board's blunder.

"Today's mistake by the Board of Elections was unfortunate," Adams tweeted Tuesday. "It is critical that New Yorkers are confident in their electoral system, especially as we rank votes in a citywide election for the first time."

Garcia, who was fleetingly thrust into second place by the incorrect ranked-choice voting report, called for a more thorough accounting of what went wrong.

"The Board of Elections' release of incorrect ranked choice votes is deeply troubling and requires a much more transparent and complete explanation. Every ranked choice and absentee vote must be counted accurately so that all New Yorkers have faith in our democracy and our government," she tweeted.

Progressive candidate Maya Wiley said this week's misstep was just the latest in a string of mistakes by the board.

"This error by the Board of Elections is not just failure to count votes properly today, it is the result of generations of failures that have gone unaddressed," Wiley said. "Today, we have once again seen the mismanagement that has resulted in a lack of confidence in results, not because there is a flaw in our election laws, but because those who implement it have failed too many times."

WNYC's Bergin said she thought the misstep would not cause voters to question the election results but that it may diminish the board's reputation in the eyes of the public.

"This agency is really the last bastion of true patronage politics in New York," she said. "There's been a push to overhaul the agency, to give the staff more authority over political appointees. But ultimately that's all up to state lawmakers to do."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Still from the film "Dream Horse" starring Toni Collette.

Larry Mantle and KPCC film critics Angie Han, Wade Major and Peter Rainer review this weekend’s new movie releases.

• "Dream Horse," in wide release & VOD (including Google Play & iTunes June 11)

• "The Dry," in select theaters (check your local listings) & VOD (including Apple TV & VUDU)

• "Milkwater," on VOD platforms (including VUDU & FandangoNow)

• "Blast Beat," in select theaters (check local listings) & VOD (including iTunes, Google Play)

• "Into The Darkness," Laemmle’s Virtual Cinema; VOD (including FandangoNow, iTunes, Google Play) 

• "New Order," in select theaters (check your local listings)

• "The New Deal For Artists," at virtual cinemas, Laemmle's Virtual Cinema June 18

• "When Hitler Stole Pink Rabbit," at Laemmle theaters (Town Center 5, Royal, Playhouse 7); Laemmle’s Virtual Cinema

• "Two Lottery Tickets," at Laemmle’s Virtual Cinema 

• "Final Account," Laemmle Theaters (Claremont 5, Playhouse 7, Town Center 5, Newhall), Century Stadium 25 and XD (Orange); in select theaters

• "The Last Days (Remastered)," on Netflix

• "Spring Blossom," at Laemmle's Virtual Cinema and Royal

• "Tomorrow’s Hope," at Laemmle’s Virtual Cinema

• "The Penny Black," at Laemmle's Virtual Cinema

• "Seance," in select theaters (check your local listings); VOD (including FandangoNow, Vudu, iTunes, Google Play)

DURING COVID: Our FilmWeek critics have been curating personal lists of their favorite TV shows and movies to binge-watch during self-quarantine. You can see recommendations from each of the critics and where you can watch them here.

Guests:

Angie Han, film critic for KPCC and deputy entertainment editor at Mashable; she tweets @ajhan

Wade Major, film critic for KPCC and CineGods.com

Peter Rainer, film critic for KPCC and the Christian Science Monitor

This content is from Southern California Public Radio. View the original story at SCPR.org.

Still of Emily Blunt and Noah Jupe in the film “A Quiet Place Part II.”; Credit: Paramount Pictures

Larry Mantle and KPCC film critics Lael Loewenstein, Christy Lemire and Charles Solomon review this weekend’s new movie releases on streaming and on demand platforms.

• "A Quiet Place Part II," in wide release

• "Cruella," in wide release & Disney+

• "Dog Gone Trouble," on Netflix

• "Pretty Guardian Sailor Moon Eternal The Movie," on Netflix June 3

• "Moby Doc," In Select Theaters (check your local listings); VOD (including FandangoNow, iTunes, Vudu); Laemmle’s Virtual Cinema June 4

• "Changing The Game," on Hulu June 1

• "Port Authority," Cinelounge Sunset Hollywood; Laemmle’s Virtual Cinema; Digital/VOD (including Vudu, Google Play, FandangoNow) June 1

• "Plan B," on Hulu

• "Borat Supplemental Reportings," on Amazon Prime Video

• "Dead Pigs," on Laemmle’s Virtual Cinema

Our FilmWeek critics have been curating personal lists of their favorite TV shows and movies to binge-watch during self-quarantine. You can see recommendations from each of the critics and where you can watch them here.

Guests:

Christy Lemire, film critic for KPCC, RogerEbert.com and co-host of the ‘Breakfast All Day’ podcast; she tweets @christylemire

Lael Loewenstein, film critic for KPCC and film columnist for the Santa Monica Daily Press; she tweets @LAELLO

Charles Solomon, film critic for KPCC, Animation Scoop and Animation Magazine

This content is from Southern California Public Radio. View the original story at SCPR.org.

Photo of Marcell Jankovics; Credit: courtesy of cartoonbrew.com

FilmWeek’s animation authority, Charles Solomon, remembers the great Hungarian animator Marcell Jankovics, who died on May 29. He died at the age of 79. Our critics also share some of the things they’ve been busy watching on various streaming platforms and why they recommend listeners check them out.  

Guests:

Amy Nicholson, film critic for KPCC, film writer for The New York Times and host of the podcast ‘Unspooled’ and the podcast miniseries “Zoom”; she tweets @TheAmyNicholson

Wade Major, film critic for KPCC and CineGods.com

Charles Solomon, film critic for KPCC, Animation Scoop and Animation Magazine

This content is from Southern California Public Radio. View the original story at SCPR.org.

Shot from the film "The Conjuring: The Devil Made Me Do It"; Credit: Warner Bros. Pictures

Larry Mantle and KPCC film critics Amy Nicholson, Wade Major and Charles Solomon review this weekend’s new movie releases on streaming and on demand platforms.

• "The Conjuring: The Devil Made Me Do It," in wide release & HBO Max

• "Spirit Untamed," in wide release

• "Edge Of The World," on VOD (including Google Play & FandangoNow)

• "All Light, Everywhere," at The Landmark Theater; Laemmle’s Playhouse 7 (Pasadena) on June 11

• "City of Ali," Laemmle’s Virtual Cinema; Laemmle’s NoHo 7 on June 17

• "Gully," In Select Theaters including Cinemark 18 and XD (Los Angeles), Cinemark 22 and IMAX (Lancaster); VOD (Youtube & Vudu) June 8

• "On The Trail Of Bigfoot: The Journey," VOD (including iTunes, Amazon Prime Video, Vudu & FandangoNOW) June 8

• "Undine," Laemmle Theaters (Playhouse 7, Newhall, Town Center 5, Royal, Claremont 5); VOD (including iTunes, Vudu, Google Play)

• "Grace And Grit," in select theaters & VOD (including FandangoNow, iTunes, Spectrum on Demand)

• "Super Frenchie," In select theaters & VOD (including Google Play, iTunes & FandangoNow)

• "Bad Tales," In select theaters; Laemmle Virtual Cinema & Monica Film Center; VOD

• "Flashback," VOD (including Vudu, FandangoNow & Spectrum on Demand)

Our FilmWeek critics have been curating personal lists of their favorite TV shows and movies to binge-watch during self-quarantine. You can see recommendations from each of the critics and where you can watch them here.

Guests:

Amy Nicholson, film critic for KPCC, film writer for The New York Times and host of the podcast ‘Unspooled’ and the podcast miniseries “Zoom”; she tweets @TheAmyNicholson

Wade Major, film critic for KPCC and CineGods.com

Charles Solomon, film critic for KPCC, Animation Scoop and Animation Magazine

This content is from Southern California Public Radio. View the original story at SCPR.org.

ANTHONY RAMOS as Usnavi in Warner Bros. Pictures’ “IN THE HEIGHTS.”; Credit: Macall Polay/Warner Bros. Pictures’

Larry Mantle and KPCC film critics Angie Han, Andy Klein, Tim Cogshell and Charles Solomon review this weekend’s new movie releases on streaming and on demand platforms.

• "In the Heights," on wide release & HBO Max

• "Holler," at Laemmle’s Monica Film Center (Santa Monica), Laemmle’s Playhouse 7 (Pasadena); VOD (including FandangoNow, Google Play & VUDU)

• "A Perfect Enemy," in select theaters (check your local listings)

• "Wish Dragon," on Netflix

• "Sublet," at Laemmle theaters (Playhouse 7, Town Center 5, Royal); Laemmle’s Virtual Cinema on June 18; VOD on July 9

• "The Hitman's Wife's Bodyguard," on wide release June 16 (they also have select earlier showtimes June 11 & 12)

• "Censor," Laemmle’s Glendale, Alamo Drafthouse Cinema (DTLA) and Landmark Westwood; VOD (including iTunes, Amazon Prime Video, YouTube) on June 18

• "La Dosis (The Dose)," on VOD/Digital (including iTunes & FandangoNow)

• "Revolution Rent," on HBO Max on June 15

• "The Misfits," In select theaters (including Universal Cinema AMC and Cinemark 18 & XD); VOD/Digital (including Vudu, Google Play) on June 15 

• "Take Me Somewhere Nice," at Laemmle’s Virtual Cinema 

• "Queen Bees," at Laemmle’s Virtual Cinema, Laemmle’s Theaters (including Glendale, Playhouse 7, Monica Film Center, Newhall & Town Center 5); VOD (including Vudu, Amazon Prime Video & Apple TV)

Our FilmWeek critics have been curating personal lists of their favorite TV shows and movies to binge-watch during self-quarantine. You can see recommendations from each of the critics and where you can watch them here.

Guests:

Tim Cogshell, film critic for KPCC, Alt-Film Guide and CineGods.com; he tweets @CinemaInMind

Andy Klein, KPCC film critic

Angie Han, film critic for KPCC and deputy entertainment editor at Mashable; she tweets @ajhan

Charles Solomon, film critic for KPCC, Animation Scoop and Animation Magazine

This content is from Southern California Public Radio. View the original story at SCPR.org.

Circus of Books storefront.; Credit: Netflix/Circus Of Books (2020)

The documentary “Circus of Books”  tells the story of two book stores, one in West Hollywood and the other in Silver Lake, operated by Karen and Barry Mason, who became accidental book sellers. They also became real pillars of the LGBTQ communties. Rachel Mason is the daughter of the masons and she’s also the filmmaker. Larry talked with Rachel about “Circus of Books” when it was first released on Netflix. Today on FilmWeek, we excerpt a portion of that conversation. 

This conversation aired during FilmWeek’s Saturday broadcast. 

Guest: 

Rachel Mason, director of the Netflix documentary ‘Circus of Books’ and daughter of Circus of Books owners Karen and Barry Mason; she tweets @RachelMasonArt

This content is from Southern California Public Radio. View the original story at SCPR.org.

Rita Moreno, as seen in the documentary “Rita Moreno: Just a Girl Who Decided to Go for It.”

Guest host John Horn and KPCC film critics Claudia Puig, Peter Rainer, Lael Loewenstein and Charles Solomon review this weekend’s new movie releases on streaming and on demand platforms.

• "Rita Moreno: Just a Girl Who Decided to Go for It," at Laemmle’s theaters (Newhall, Town Center 5, NoHo 7, Claremont 5, Playhouse 7) and other select theaters 

• "Les Nôtres," at Laemmle’s Royal and Laemmle’s Virtual Cinema 

• "Rise Again: Tulsa And The Red Summer," premieres on National Geographic June 18 at 6pm PT & on Hulu June 19

• "Luca," at the El Capitan Theater (Hollywood) & Disney+

• "The Sparks Brothers," in wide release 

• "Sisters on Track," on Netflix June 24

• "Fatherhood," on Netflix

• "Truman & Tennessee: An Intimate Conversation," at Landmark’s Nuart Theater & Virtual cinemas 

• "Sweet Thing," Laemmle’s Royal and Laemmle’s Virtual Cinema

• "Summer of 85," at Laemmle’s theaters (Playhouse 7, Royal and Town Center 5) 

• "12 Mighty Orphans" in wide release

Our FilmWeek critics have been curating personal lists of their favorite TV shows and movies to binge-watch during self-quarantine. You can see recommendations from each of the critics and where you can watch them here.

With guest host John Horn 

Guests:

Claudia Puig, film critic for KPCC and president of the Los Angeles Film Critics Association (LAFCA); she tweets @ClaudiaPuig

Lael Loewenstein, film critic for KPCC and film columnist for the Santa Monica Daily Press; she tweets @LAELLO

Peter Rainer, film critic for KPCC and the Christian Science Monitor

Charles Solomon, film critic for KPCC, Animation Scoop and Animation Magazine

This content is from Southern California Public Radio. View the original story at SCPR.org.

Edgar Wright attends the 55th Annual International Cinematographers Guild Publicists Awards at The Beverly Hilton Hotel on March 2, 2018 in Beverly Hills, California.; Credit: Tommaso Boddi/Getty Images

The joke about Sparks — if you’ve even heard of them — is that it’s the best British band to come out of America. That confusion is why Edgar Wright, the director of “Baby Driver” and “Shaun of the Dead,” wanted to make his first documentary about the group, headed by brothers Ron and Russell Mael. Quite simply, Wright was tired of explaining who the band was and why he loves them. His documentary, called “The Sparks Brothers,” premiered at this year’s Sundance Film Festival. John Horn talked with Wright after its January premiere about his personal connection to the band, how he connected with the brother, the editing process of the documentary and more. The film is in theaters now.

With guest host John Horn

Guest: 

Edgar Wright, director of the new documentary “The Sparks Brothers;” he tweets @edgarwright

This content is from Southern California Public Radio. View the original story at SCPR.org.

Michelle Rodriguez (L) and Vin Diesel (R) in "F9: The Fast Saga"; Credit: Universal Pictures

Larry Mantle and KPCC film critics Amy Nicholson and Christy Lemire review this weekend’s new movie releases on streaming and on-demand platforms.

• "F9: The Fast Saga," in wide release

• "Summer of Soul, "at El Capitan Theatre June 25-July 6; Hulu on July 2

• "Zola," in wide release

• "Sweat," at Laemmle’s NoHo 7

• "LFG," on HBO Max  

• "Rebel Hearts," Laemmle’s Glendale; on Discovery+ on June 27

• "I Carry You with Me," AMC Sunset 5 (West Hollywood), The Landmark (West LA); Laemmle Playhouse 7 & Town Center 5 on July 2 (additional Laemmle theaters on July 9)

• "Fathom," on Apple TV+, Laemmle’s Monica Film Center

• "Wolfgang," on Disney+

Our FilmWeek critics have been curating personal lists of their favorite TV shows and movies to binge-watch during self-quarantine. You can see recommendations from each of the critics and where you can watch them here.

Guests:

Amy Nicholson, film critic for KPCC, film writer for The New York Times and host of the podcast ‘Unspooled’ and the podcast miniseries “Zoom”; she tweets @TheAmyNicholson

Christy Lemire, film critic for KPCC, RogerEbert.com and co-host of the ‘Breakfast All Day’ podcast; she tweets @christylemire

This content is from Southern California Public Radio. View the original story at SCPR.org.

Screenshot of the event "FilmWeek & Chill: ‘Airplane!’" broadcasted on June 3, 2021.

The iconic 1980 film “Airplane!” from the ZAZ directing team, Jim Abrahams, David Zucker and Jerry Zucker parodies the plot and characters from the 1957 disaster flick “Zero Hour!” It broke out as a leading example of comedy done right and one of the funniest films of the 80s. It was the ZAZ team’s feature directorial debut. I talked with the directors during our virtual film series, FilmWeek and Chill, along with the film’s stars Robert Hays and Lorna Patterson Lembeck, casting director Joel Thurm and KPCC’s own Tim Cogshell and Christy Lemire. Today on FilmWeek, we bring you a portion of the conversation.

You can watch the entire FilmWeek and Chill event here.

Guests:

Jim Abrahams, co-director of “Airplane!” and member of the directing team Zucker, Abrahams and Zucker (ZAZ)

Tim Cogshell, film critic for KPCC, Alt-Film Guide and CineGods.com; he tweets @CinemaInMind

Robert Hays, actor who played Ted Striker in "Airplane!"

Lorna Lembeck, actress who played Randy the singing stewardess in “Airplane!”

Christy Lemire, film critic for KPCC, RogerEbert.com, and co-host of the “Breakfast All Day” podcast; she tweets @christylemire

Joel Thurm, casting director for "Airplane!"

David Zucker, co-director of “Airplane!” and member of the directing team Zucker, Abrahams and Zucker (ZAZ)

Jerry Zucker, co-director of “Airplane!” and member of the directing team Zucker, Abrahams and Zucker (ZAZ)

This content is from Southern California Public Radio. View the original story at SCPR.org.

Shot from the film “The Boss Baby: Family Business”; Credit: Dreamworks

Larry Mantle and KPCC film critics Lael Loewenstein, Wade Major and Charles Solomon review this weekend’s new movie releases on streaming and on demand platforms.

• "The Forever Purge," in wide release

• "The Boss Baby: Family Business," in wide release & on Peacock

• "Long Story Short," at Laemmle’s Glendale; & on VOD/Digital (including Vudu, FandangoNow & Google Play)

• "The Tomorrow War," on Amazon Prime Video

• "The One And Only Dick Gregory," premieres on Showtime July 4 at 9 pm PT, available on demand on Showtime following that

• "No Sudden Move," on HBO Max

• "The Ladykillers (Originally released in 1955)," at Laemmle Theaters (Royal, Town Center 5, Playhouse 7)

• "America: The Motion Picture," on Netflix

Our FilmWeek critics have been curating personal lists of their favorite TV shows and movies to binge-watch during self-quarantine. You can see recommendations from each of the critics and where you can watch them here.

Guests:

Lael Loewenstein, film critic for KPCC; she tweets @LAELLO

Wade Major, film critic for KPCC and CineGods.com

Charles Solomon, film critic for KPCC, Animation Scoop and Animation Magazine

This content is from Southern California Public Radio. View the original story at SCPR.org.

Vancouver-based minerals explorer Prosper Gold Corp. (TSVX: PGF; OTCQB: PGXFF) is focused on its district-scale Cyprus copper-gold project in north-central British Columbia. One analyst says the results of a recent geophysical survey put the stock in an excellent position.

Michael Ballanger of GGM Advisory Inc. shares an update on his thoughts on the gold, silver, and copper sectors.

Global Analyst Adrian Day reviews financials and preliminary reports from some major resource companies as well as developments at others. He also answers a reader's question on Newmont: is it a good buy after the sharp drop after its earnings?

Michael Ballanger of GGM Advisory Inc. shares his thoughts on the silver market and shares one copper stock he believes is a Strong Speculative Buy even though the stock is currently halted.

Full Text:

Earth's magnetic field seems steady and true -- reliable enough to navigate by. Yet, largely hidden from daily life, the field drifts, waxes and wanes. The magnetic North Pole is currently shifting toward Siberia, forcing the Global Positioning System that underlies modern navigation to update its software sooner than expected. Every several hundred thousand years, the magnetic field dramatically shifts and reverses its polarity. Magnetic north flips to the geographic South Pole and, eventually, back again. This reversal has happened countless times over Earth's history, but scientists' understanding of why and how the field reverses is limited. The researchers find that the most recent field reversal 770,000 years ago took at least 22,000 years to complete, several times longer than previously thought. The results call into question controversial findings that some reversals could occur within a human lifetime.

Image credit: Brad Singer

Full Text:

Machine learning algorithms can sometimes do a great job with a little help from human expertise, at least in the field of materials science. In many specialized areas of science, engineering and medicine, researchers are turning to machine learning algorithms to analyze data sets that have grown too large for humans to understand. In materials science, success with this effort could accelerate the design of next-generation advanced functional materials, where development now usually depends on old-fashioned trial and error. By themselves, however, data analytics techniques borrowed from other research areas often fail to provide the insights needed to help materials scientists and engineers choose which of many variables to adjust -- and the techniques can't account for dramatic changes such as the introduction of a new chemical compound into the process. In a new study, researchers explain a technique known as dimensional stacking, which shows that human experience still has a role to play in the age of machine intelligence. The machines gain an edge at solving a challenge when the data to be analyzed are intelligently organized based on human knowledge of what factors are likely to be important and related. "When your machine accepts strings of data, it really does matter how you are putting those strings together," said Nazanin Bassiri-Gharb, the paper's corresponding author and a scientist at the Georgia Institute of Technology. "We must be mindful that the organization of data before it goes to the algorithm makes a difference. If you don't plug the information in correctly, you will get a result that isn't necessarily correlated with the reality of the physics and chemistry that govern the materials."

Image credit: Rob Felt/Georgia Tech

Full Text:

Bridges make travel faster and more convenient, but, in an earthquake, these structures are subject to forces that can cause extensive damage and make them unsafe. Now civil and environmental engineer Petros Sideris of Texas A&M University is leading a National Science Foundation (NSF)-funded research project to investigate the performance of hybrid sliding-rocking (HSR) columns. HSR columns provide the same support as conventional bridge infrastructure columns but are more earthquake-resistant. HSR columns are a series of individual concrete segments held together by steel cables that allow for controlled sliding and rocking. This allows the columns to shift without damage, while post-tensioning strands ensure that at the end of an earthquake the columns are pushed back to their original position. Conventional bridges are cast-in-place monolithic concrete elements that are strong but inflexible. Structural damage in these bridge columns, typically caused by a natural disaster, often forces a bridge to close until repairs are completed. But bridges with HSR columns can withstand large earthquakes with minimal damage and require minor repairs, likely without bridge closures. Such infrastructure helps with post-disaster response and recovery and can save thousands in taxpayer dollars. In an earthquake, HSR columns provide "multiple advantages to the public," Sideris said. "By preventing bridge damage, we can maintain access to affected areas immediately after an event for response teams to be easily deployed, and help affected communities recover faster. In mitigating losses related to post-event bridge repairs and bridge closures, more funds can be potentially directed to supporting the recovery of the affected communities." According to Joy Pauschke, NSF program director for natural hazards engineering, "NSF invests in fundamental engineering research so that, in the future, the nation's infrastructure can be more resilient to earthquakes, hurricanes, and other forces of nature."

Image credit: Texas A&M University

Source: Ron Struthers 10/22/2024

Silver is up again today, currently $34.72 up about $0.64.

This confirms yesterdays breakout and if you remember back in April or early May, I highlighted the breakout from a cup and handle formation and that would lead to a major upside move. This is not confirmed and I see $50 as the near term target.

Similar to gold, investor participation is still quite low. Volumes into the silver etf SLF are up some but no where near 2020 volumes. There are all kinds of silver bullion available at the coin dealer I use.

Our silver stocks are not dragging down the average performance of our gold stocks as much now, and I would like to add another one to the list.

Coeur Mining

_{Shares Outstanding - 399 million}

Coeur Mining Inc. (CDE:NYSE) has been a laggard in this bull rally thus far because it is not well understood. Investors seem to remember more of their legacy than who they are today. Many investors know Coeur as a silver company, but for many years now, most of their revenue and profits have come from gold. Around $7.20, the stock is well below its 2021 highs of around $11.50 and 2016 highs of $16

In Q2 2024, gold sales were $154.1 million, and silver sales were $67.9 million. This makes gold sales almost 70% of revenues. The stock should have responded more to the rising gold price, but as I said, I think investors were still viewing Coeur as mostly a silver company.

That said, they do have large leverage to silver because their resource base they are almost 60% silver. The company is maintaining its full-year production guidance ranges of 310,000 - 355,000 gold ounces and 10.7 - 13.3 million silver ounces. Full-year CAS guidance at Palmarejo and Wharf has been reduced to reflect strong cost management efforts, while Rochester's second-half CAS guidance ranges have been increased to reflect the timing of ounces placed under leach.

Other significant news on the silver front was just a couple of weeks ago, on October 4. Coeeur announced that they entered into a definitive agreement to acquire all of the issued and outstanding shares of SilverCrest pursuant to a court-approved plan of arrangement.

Under the terms of the Agreement, SilverCrest shareholders will receive 1.6022 Coeur common shares for each SilverCrest common share. The Exchange Ratio implies a consideration of $11.34 per SilverCrest common share, based on the closing price of Coeur common shares on the New York Stock Exchange ("NYSE") on October 3, 2024. This represents an 18% premium based on 20-day volume-weighted average prices of Coeur and SilverCrest each as of October 3, 2024.

It turns out, this was a very well timed acquisition ahead of the silver price rise and it will make Coeur the world's largest pure silver producer at about 21 million ounces per year. Their silver production should be neck and neck or just a little behind Pan American Silver not shown on this graphic.

Another key positive fundamental is the expansion of their Rochester Mine this year. In mid-September, they announced that the new three-stage crushing circuit continues to deliver greatly enhanced levels of flexibility to accommodate the full range of mined ore in Rochester.

For the month of August, approximately 2.7 million tons were placed on the new Stage VI leach pad, representing a 39% increase over July placement levels. Rochester remains on track to place 7.0 – 8.0 million tons per quarter during the second half of 2024 and to achieve its full-year 2024 production guidance of 4.8 – 6.6 million ounces of silver and 37,000 – 50,000 ounces of gold.

Rochester is the largest open pit heap leach operation in North America and the largest silver reserve asset in the U.S.

At the end of 2023, Coeur had 3.2 million ounces of proven and probable gold reserves and 243.9 million ounces of silver. At the long-term reference of 60 to 1 ratio, their reserves are 58% silver and 42% gold.

With the significant expansion at Rochester and the acquisition of SilverCrest it will make a significant positive effect to increased profits and cash flow. According to Coeur's presentation, using Factset Street Research data, they will be the leader among peers. The Pro Forma adding SilverCrest is significant. The higher silver price is more gravy on top.

The chart looks good, too. Volume is picking up, and it looks like the stock will break through the resistance area and head to $11.

You can get some more leverage with Call options. Because this is a low-priced stock, I would take advantage of low premiums on long dates. The December 2025 $5.50 Call option is about $2.75 and is $1.87 in the money, so a premium of less than $1.00 for almost 14 months. Nektar Therapeutics (NKTR:NASDAQ)

Nektar Therapeutics

_{Recent Price - $1.41}

_{Entry Price- $0.68}

_{Opinion - Sell}

There is nothing wrong with Nektar Therapeutics (NKTR:NASDAQ), but I am concerned we could get a significant market correction, and I don't like the fact the stock has not done better in a bullish market.

That said, I think this reflects how concentrated this bull market is and does not have good breadth.

The stock is just below cash value but the stock is near resistance on the chart and besides that we have over 100% profits in about 8 months, lets take them.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Ron Struthers: I or members of my immediate household or family, own securities of: Couer Mining. I determined which companies would be included in this article based on my research and understanding of the sector.
2. Statements and opinions expressed are the opinions of the author and not of Streetwise Reports, Street Smart, or their officers. The author is wholly responsible for the accuracy of the statements. Streetwise Reports was not paid by the author to publish or syndicate this article. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Any disclosures from the author can be found below. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
3. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
4. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Struthers Resource Stock Report Disclosures

All forecasts and recommendations are based on opinion. Markets change direction with consensus beliefs, which may change at any time and without notice. The author/publisher of this publication has taken every precaution to provide the most accurate information possible. The information & data were obtained from sources believed to be reliable, but because the information & data source are beyond the author's control, no representation or guarantee is made that it is complete or accurate. The reader accepts information on the condition that errors or omissions shall not be made the basis for any claim, demand or cause for action. Because of the ever-changing nature of information & statistics the author/publisher strongly encourages the reader to communicate directly with the company and/or with their personal investment adviser to obtain up to date information. Past results are not necessarily indicative of future results. Any statements non-factual in nature constitute only current opinions, which are subject to change. The author/publisher may or may not have a position in the securities and/or options relating thereto, & may make purchases and/or sales of these securities relating thereto from time to time in the open market or otherwise. Neither the information, nor opinions expressed, shall be construed as a solicitation to buy or sell any stock, futures or options contract mentioned herein. The author/publisher of this letter is not a qualified financial adviser & is not acting as such in this publication.

( Companies Mentioned: CDE:NYSE, NKTR:NASDAQ, )

Source: Streetwise Reports 10/31/2024

Healthcare artificial intelligence (AI) company Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) announced that it has closed a non-brokered private placement for aggregate gross proceeds of CA$1.95 million.

A total of 2,138,766 special warrants of the company were offered at CA$0.75 per special warrant with proceeds of CA$1.6 million. The company also said 466,666 units of the company were offered at CA$0.75 per unit for proceeds of CA$349,999.50.

The company said it intends to use the proceeds for working capital purposes.

"We are very encouraged by the support from our investors with their overwhelming response to the financing and the subsequent over-subscription," Chief Executive Officer Dr. Essam Hamza said. "This money will help expedite our aggressive growth plans over the next year."

Technical Analyst Clive Maund noted on October 9* that the outlook for the company is "outstandingly bright" because it has "positioned itself to revolutionize the healthcare industry using AI and advanced machine learning technologies."

The company "is set to transform the current archaic system so that no longer do patients have to sit for hours in waiting rooms to see a doctor or doctors, and doctors and other healthcare professionals have to suffer a crushing burden of often unnecessary patient visits and tedious repetitive bureaucracy," he wrote. "Treatment AI's platform will take care of most of it."

Healthcare Professionals Worldwide Contribute to AI Engine

Treatment.com AI said it is a company utilizing AI and best clinical practices with a goal to positively improve the healthcare sector and impact current inefficiencies and challenges.

With the input of hundreds of healthcare professionals globally, Treatment.com AI said it has built a comprehensive, personalized healthcare AI engine called the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM is designed to provide tested clinical information and support to all healthcare professionals, as well as providing recommended tests (physical and lab), X-rays, and billing codes.

According to the company, the GLM will help healthcare professionals (doctors, nurses, and pharmacists) reduce administrative burdens, creating more time for face-to-face patient appointments.

"AI is set to expedite and streamline the healthcare industry, making it vastly more efficient for the benefit of both healthcare professionals and patients," Maund noted.

The Catalyst: A 'Profound Transformation' in the Industry

AI has an important role to play in the healthcare offerings of the future, a 2019 report from the National Center of Biomechanical Medicine listed in the National Library of Medicine said. "In the form of machine learning, it is the primary capability behind the development of precision medicine, widely agreed to be a sorely needed advance in care."

Healthcare organizations are increasingly turning to the technology to address both clinical and administrative challenges. The combination of generative AI, as noted by Appinventiv in September, and operational tools like those developed by Treatment.com AI are driving this transformation.

Generative AI is "catalyzing a profound transformation within the healthcare industry" by generating synthetic data, predicting patient outcomes, and optimizing treatment plans, all of which revolutionize clinical decision-making processes, Appinventiv reported. This aligns with Treatment.com AI's announced collaboration with SPRYT on September 17 whereby integrating SPRYT’s AI receptionist "Asa" with its GLM has the goal of enhancing patient access to healthcare while reducing administrative burdens.

A CBC report from September 16 said real-world applications of AI in healthcare are already showing promising results. Dr. Muhammad Mamdani, co-author of a study on the topic, expressed optimism about AI's ability to "complement clinicians' own judgment and lead to better outcomes for fragile patients."

According to a report by Markets and Markets, the global AI in healthcare market in total was valued at US$20.9 billion this year and will reach an estimated US$148.4 billion by 2029, a compound annual growth rate (CAGR) of 48.1%.

"The growth of AI in the healthcare market is driven by the generation of large and complex healthcare datasets, the pressing need to reduce healthcare costs, improving computing power and declining hardware costs, and the rising number of partnerships and collaborations among different domains in the healthcare sector, and growing need for improvised healthcare services due to imbalance between healthcare workforce and patients," the report said.

Analyst: A 'Genuine Breakout Soon' for Stock

Maund said its stock charts are also looking "very positive indeed" for the company.

Of particular note is the big upleg late in June and early in July on persistent heavy volume, which broke the price clear above the May high and drove volume indicators steeply higher," the analyst noted. [OWNERSHIP_CHART-10594]

"This is very bullish price/volume action, especially as the volume indicators have not just held up but have actually advanced as the price has reacted back in a normal manner from the early July high to arrive at a support level where it has stabilized above the 200-day moving average in readiness for renewed advance, so the correction looks like a large bull Pennant that, as it is now closing up, promises renewed advance soon," continued Maund, who said holders should stay long and rated the stock a Strong Buy that "is thought worth going overweight on."

"The June-July rally must be classed as a 'preliminary' breakout," he noted. "But that said, the exceptionally bullish price/volume action of recent months does promise a genuine breakout soon that looks set to lead to a sustained and substantial uptrend."

Ownership and Share Structure

According to Sedi.ca, insiders own approximately 8% of Treatment.com AI. Retail investors own the remaining 92%.

The company has 48.84 million outstanding common shares and has 41.3 million free float traded shares.

As of October 31, the market cap is approximately CA$31.75 million. Over the past 52 weeks, the company traded between CA$0.355 and CA$1.11 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Treatment.com AI has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Treatment.com AI.
3. Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

* Disclosure for quotes from the Clive Maund source October 9, 2024

1. For the quote (sourced on October 9, 2024), the Company has paid Street Smart, an affiliate of Streetwise Reports, US$1,500.
2. Author Certification and Compensation: [Clive Maund of clivemaund.com] is being compensated as an independent contractor by Street Smart, an affiliate of Streetwise Reports, for writing the article quoted. Maund received his UK Technical Analysts’ Diploma in 1989. The recommendations and opinions expressed in the article accurately reflect the personal, independent, and objective views of the author regarding any and all of the designated securities discussed. No part of the compensation received by the author was, is, or will be directly or indirectly related to the specific recommendations or views expressed.

Clivemaund.com Disclosures

The quoted article represents the opinion and analysis of Mr. Maund, based on data available to him, at the time of writing. Mr. Maund's opinions are his own, and are not a recommendation or an offer to buy or sell securities. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stock market analyst, Clive Maund is not a Registered Securities Advisor. Therefore Mr. Maund's opinions on the market and stocks cannot be only be construed as a recommendation or solicitation to buy and sell securities.

( Companies Mentioned: TRUE:CSE; TREIF:OTCMKTS;939:FRA, )